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ABSTRACT 
THE CONSEQUENCES OF DISRUPTING THE MDM2-P53 BALANCE IN 
HEMATOPOIESIS 
 
Publication No.______ 
 
Hussein A. Abbas 
Supervisory Professor: Guillermina Lozano, Ph.D. 
 
 The bone marrow accommodates hematopoietic stem cells and progenitors. 
These cells provide an indispensible resource for replenishing the blood 
constituents throughout an organism’s life. A tissue with such a high turn-over rate 
mandates intact cycling checkpoint and apoptotic pathways to avoid inappropriate 
cell proliferation and ultimately the development of leukemias. p53, a major tumor 
suppressor, is a transcription factor that regulates cell cycle, and induces apoptosis 
and senescence. Mice inheriting a hypomorphic p53 allele in the absence of Mdm2, 
a p53 inhibitor, have elevated p53 cell cycle activity and die by postnatal day 13 due 
to hematopoietic failure. Hematopoiesis progresses normally during embryogenesis 
until it moves to the bone marrow in late development. Increased oxidative stress in 
the bone marrow compartment postnatally is the impediment for normal 
hematopoiesis via activation of p53. p53 in turn stimulates the generation of more 
reactive oxygen species and depletes bone marrow cellularity. Also, p53 exerts 
various defects on the hematopoietic niche by increasing mesenchymal lineage 
populations and their differentiation. Hematopoietic defects are rescued with 
     viii 
antioxidants or when cells are cultured at low oxygen levels. Deletion of p16 
partially rescues bone marrow cellularity and progenitors via a p53-independent 
pathway. Thus, although p53 is required to inhibit tumorigenesis, Mdm2 is required 
to control ROS-induced p53 levels for sustainable hematopoiesis and survival 
during homeostasis.  
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INTRODUCTION 
 
p53: the tumor suppressor gene 
Discovery of p53 
p53 is one of the most studied genes in the genetics of cancer due to its high 
mutation rate in familial and somatic cancers, and its association with viral 
oncogenes. Discovered in 1979, p53 was identified as a protein with an 
approximate weight of 53,000 Daltons in extracts of simian virus 40 (SV40) 
transformed cell lines (DeLeo, Jay et al. 1979; Kress, May et al. 1979; Lane and 
Crawford 1979; Linzer and Levine 1979). Specifically, p53 protein formed a complex 
with the SV40 large T antigen. Within two years of its discovery, a plethora of 
human and rodent transformed cell lines were tested for p53 expression and many 
showed elevated levels of this protein (regardless of mode of transformation), 
contrary to little or no expression in normal cells (Crawford, Pim et al. 1981). 
Although these studies collectively correlated p53 expression with transforming 
events, p53’s direct role in transformation remained unclear. 
In 1984, the p53 cDNA was cloned, and the predicted amino acid sequence 
showed homology to a tyrosine kinase acceptor site and, to a lesser extent, to the 
myc oncogene (Bienz, Zakut-Houri et al. 1984; Czosnek, Bienz et al. 1984; Jenkins, 
Rudge et al. 1984). Hence, molecular cancer biologists at that time became 
perplexed by the uncertainty of p53’s characteristics. Several labs overexpressed 
the cloned cDNA and independently showed that p53 can immortalize and 
transform normal cell lines (Eliyahu, Raz et al. 1984; Jenkins, Rudge et al. 1984; 
Lane 1984). Varda Rotter’s work in late 1984 confirmed that p53 can “play a causal 
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role in the conversion of normal fibroblasts into tumorigenic cells” upon cooperation 
with other known oncogenes such as ras (Parada, Land et al. 1984). It took several 
years for the field to realize that mutations in the cDNAs used for these 
transformation studies had concealed the actual role of p53. 
 
Rectifying p53’s role in tumorigenesis 
Skepticism about p53’s transforming role culminated when Levine’s lab 
showed for the first time that overexpressing a wildtype clone of p53 can actually 
suppress, rather than promote transformation of rodent cell lines (Finlay, Hinds et 
al. 1989). Concurrently, analysis of the p53 gene status in human tumor samples 
evidently supported the Knudson’s two-hit hypothesis of a tumor suppressor model 
(Knudson 1971; Vogelstein 1990). Specifically, colorectal cancer patients had one 
mutant allele of p53 while the other allele was lost (Baker, Fearon et al. 1989; 
Vogelstein, Fearon et al. 1989). These experiments instigated a paradigm shift in 
describing the bona fide role of p53 in transforming events. Thus, by the late 1980’s, 
p53 was finally recognized as a tumor suppressor and not as an oncogene (Finlay, 
Hinds et al. 1989). 
 
Early p53 mouse models 
In 1989, with the use of mouse transgenic models, mutant p53 was 
overexpressed for the first time in vivo (Lavigueur, Maltby et al. 1989). 20% of the 
transgenic-mutant p53 mice had high rate of tumors providing direct evidence that 
mutations in p53 may promote oncogenesis (Lavigueur, Maltby et al. 1989). During 
that same time frame, p53 germline mutations were detected in several families with 
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Li-Fraumeni syndrome causing an interest in analyzing p53 status in other sporadic 
tumors as well (Nigro, Baker et al. 1989; Malkin, Li et al. 1990). Another compelling 
piece of evidence for the role of p53 as a tumor suppressor came from generation 
of a p53-knock out mouse (Donehower, Harvey et al. 1992). p53-null mice were 
viable and with no apparent developmental defects, although a small fraction 
exhibited exencephaly (Donehower, Harvey et al. 1992; Sah, Attardi et al. 1995). 
The loss of p53, on the other hand, predisposed the mice to lymphomas and 
sarcomas and all p53-null mice died by 8 months of age due to tumor burden 
(Donehower, Harvey et al. 1992). Interestingly, loss of a single p53-allele still 
predisposed mice to tumorigenesis, but with a delayed onset and with higher 
frequency of sarcomas rather than lymphomas as compared to p53-null mice 
(Harvey, McArthur et al. 1993).  
 
These p53 mouse models showed that although p53 was not required for 
embryonic development, it was indispensible to suppress tumorigenesis in mice. 
Analysis of human tumor samples provided compelling evidence for the requirement 
of most tumors to disrupt the p53 pathway to initiate or progress. Additional studies 
were performed to delineate how p53 confers its tumor suppressor activities. 
 
Tumor suppressor functions of p53 
DNA damage activates p53 
p53 is a stress response gene that binds DNA as a tetramer in a sequence 
specific manner and transactivates a plethora of genes (Bargonetti, Friedman et al. 
1991; Kern, Kinzler et al. 1991; el-Deiry, Kern et al. 1992). Oncogeneic, hypoxic, 
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and metabolic stresses instigate p53’s activity (Junttila and Evan 2009). Cellular 
insults such as reactive oxygen species (ROS) can induce DNA damage and 
subsequently activate p53 (Ko and Prives 1996). The first evidence for a p53- 
dependent response to DNA damage came from studies on UV-treated non-
transformed cells (Maltzman and Czyzyk 1984). Specifically, post-translational 
modifications stabilized p53 protein levels in these cells. p53 activation maintains 
the genomic integrity via induction of apoptosis, cell cycle arrest, differentiation or 
senescence (Ko and Prives 1996).  
 
Apoptosis 
The role of p53 in induction of apoptosis was first observed in myeloid 
leukemic cells that overexpressed wildtype p53 (Yonish-Rouach, Resnitzky et al. 
1991). Furthermore, exposure of thymocytes to ionizing radiation induces p53-
dependent apoptosis as loss of p53 protects against radiation-induced cell death 
(Lee and Bernstein 1993; Lowe, Schmitt et al. 1993). Apoptosis confers a major 
tumor suppressor activity to eradicate defective cells and avoid propagation of 
mutations in cells. Mechanistically, p53 binds the promoters of apoptotic genes such 
as Noxa, Bax and Puma (Miyashita, Krajewski et al. 1994; Oda, Ohki et al. 2000; 
Nakano and Vousden 2001). These proteins promote activation of the intrinsic 
apoptotic pathway initiated in the mitochondria through cytochrome c release and 
caspase proteins cleavage (Reviewed in(Kroemer and Reed 2000). Apoptotic 
activity of p53 can also be mediated by the extrinsic apoptotic pathway via 
regulation of some of its elements (Fridman and Lowe 2003). For instance, Fas, a 
death receptor, and its ligand are both direct targets of p53 and are important 
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players in the extrinsic pathway of apoptosis (Owen-Schaub, Zhang et al. 1995; 
Maecker, Koumenis et al. 2000).  
 
Cell cycle arrest 
Treatment of leukemic cells harboring wildtype p53 alleles with DNA 
damaging agents induces a G1 arrest and indicates that inhibiting cell cycle 
progression is another mechanism for the tumor suppressor activity of p53 (Kastan, 
Onyekwere et al. 1991). The major cell cycle arrest target of p53 is p21, a cyclin-
dependent kinase (Cdk) inhibitor (el-Deiry, Tokino et al. 1993). p21 inhibits G1 to S 
transition of cell cycle by disrupting the activation of Cyclin E- and Cyclin A- Cdk 
complexes (Dulic, Kaufmann et al. 1994). p53 can also arrest cells in G2 via 
transactivation of GADD45 and 14-3-3σ (Hermeking, Lengauer et al. 1997; Wang, 
Zhan et al. 1999). The importance of cell cycle arrest in tumor suppressor activity of 
p53 is supported by the generation of p53515C/515C mice (Liu, Parant et al. 2004). 
p53515C allele mimics a rare p53 mutation (Arginine to Proline) in human p53 at 
amino acid 175 that lacks apoptotic activity but still retains the cell cycle arrest 
activity (Ludwig, Bates et al. 1996; Rowan, Ludwig et al. 1996). p53515C/515C mice 
are tumor prone but with longer latency than p53–/– mice (Liu, Parant et al. 2004). 
These experiments provide compelling evidence that the cell cycle arrest activity of 
p53 is indeed tumor-suppressive but it is not sufficient to completely inhibit 
tumorigenesis.  
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Differentiation and senescence 
p53 also has a  role in differentiation which is exemplified in the lymphoid 
system (Shaulsky, Goldfinger et al. 1991). Pre-B cells can be induced to a more 
mature state by introduction of wildtype p53 (Shaulsky, Goldfinger et al. 1991). This 
is indeed a remarkable observation given the high rate of DNA rearrangements and 
DNA breaks occurring during the process of B cell development (Ko and Prives 
1996). In addition to the previously mentioned p53 tumor suppressor activities, p53 
can alternatively induce senescence. Although the mechanisms underlying p53 
induction of senescence remains unclear, most studies suggest that it is mediated 
via p53’s transactivation of p21, followed by induction of p16 (el-Deiry, Tokino et al. 
1993; Beausejour, Krtolica et al. 2003). In the absence of p53, cells can still 
undergo senescence but it is generally delayed compared to cells with wildtype p53 
(Bond, Wyllie et al. 1994).   
 
The molecular events that dictate which pathway p53 activates following 
DNA damage remain unclear for the most part, although cell type and tissue 
specific modifiers seem to be of high importance (Midgley, Owens et al. 1995; 
Haupt, Barak et al. 1996; Prives and Hall 1999). Additionally, the interaction of p53 
with its negative regulators may influence p53 binding to different promoters (Kruse 
and Gu 2009). Another speculation is that minor changes in p53 levels may alter the 
cell fate to either activate cell cycle arrest or apoptosis. Specifically, as p53 levels 
increase in the cell, there will be greater propensity for p53 to activate pro-apoptotic 
rather than cell cycle arrest genes (Vousden 2000; Barboza, Iwakuma et al. 2008).  
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p53: “guardian of the genome” 
Retrospectively, the aforementioned activities specify the tumor suppressor 
activities of p53 to maintaining the genomic stability of the cell. Hence, it is not 
surprising that p53 was dubbed as “guardian of the genome” (Lane 1992). This 
moniker was used due to prevalence of aberrant genetic amplifications and 
aneuploidy in cells lacking p53 (Livingstone, White et al. 1992). p53 loss confers 
checkpoint defects and disruption of genetic integrity, allowing uninhibited 
proliferative capacity and cancer initiation (Fridman and Lowe 2003). Upon DNA 
damage, cell cycle arrest creates a brake and presumably provides sufficient time 
for repair. Alternatively, the damaged cell undergo apoptosis or enter irreversible 
arrest or senescence. The role of differentiation in tumor suppression remains 
unclear and could have more of a developmental significance. Taken as a whole, 
the versatile activities of p53 converge towards maintaining the genomic stability 
and prevention of error propagation. 
 
The structural biology of p53 
N-terminus of p53 
 Given the remarkable role of p53 in tumor suppression, understanding the 
structure of this protein is essential (Figure 1). The human p53 protein contains 393 
amino acid residues and is longer by 2 residues than the mouse homolog (Zakut-
Houri, Bienz-Tadmor et al. 1985). Five major domains have been identified in the 
p53 protein that spread among three distinct regions: the acidic N-terminus, the 
central domain and the carboxyl domain. The N-terminus contains the 
transactivation (TA) domain and a proline-rich (PR) domain. The TA domain 
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interacts with the chromatin remodeling proteins and the transcriptional machinery 
(Thut, Chen et al. 1995). Additionally, this region is important for the stability of p53 
via interactions with p53’s negative regulators and for postranslational 
modifications, such as phosphorylation (Meek 1994; Haupt, Maya et al. 1997; 
Kubbutat, Jones et al. 1997). The second domain in the N-terminus, the PR domain, 
is required for p53’s apoptotic activity (Venot, Maratrat et al. 1998). The PR domain 
also acts as a spacer region connecting the TA domain with the next domain: the 
DNA-Binding Domain (DBD) (Joerger and Fersht 2008). 
 
Central region: DNA binding domain 
 The DBD is the central portion of p53’s protein and mediates p53 binding to 
DNA in a sequence specific manner (el-Deiry, Kern et al. 1992; Zambetti, Bargonetti 
et al. 1992). SV40 binds p53 at its DBD, suggesting that this binding renders p53 
transcriptionally nonfunctional (Jenkins, Chumakov et al. 1988). Also, missense 
mutations are common in the DBD and inactivate p53’s ability to bind DNA and 
suppress tumorigenesis. These mutations confer gain-of-function phenotypes as 
p53 mutant cells have increased metastasis (Raycroft, Wu et al. 1990; Brosh and 
Rotter 2009). Hence, it is not surprising that the majority of p53 mutations occur in 
its DBD with highest mutation frequency rate at codons R248 and R273, followed by 
R175 in humans (Figure 1) (Hollstein, Shomer et al. 1996); http://www-p53.iarc.fr/). 
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*Figure 1. p53 domains and hot spot mutations. TA = transactivation domain; 
PR= Proline Rich domain; DBD = DNA binding domain; Tet = Tetramerization 
domain; Reg= carboxy-terminal Regulatory domain. Most p53 mutations occur in its 
DBD and their frequencies and number of mutations reported are noted. 
 
*Reprinted by permission from Macmillan Publishers Ltd: Nature Reviews Cancer 9, 701-713 
(October 2009) doi:10.1038/nrc2693.  Figure 2a. 
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C-terminus 
  The third region of p53 is comprised of many basic amino acid residues and 
contains the tetramerization (TET) domain and the carboxy-terminal regulatory 
(Reg) domain. This region is subject to post-translational modifications such as 
acetylation and phosophorylation following DNA damage (Meek 1994; Prives and 
Hall 1999; McKinney, Mattia et al. 2004; Krummel, Lee et al. 2005; Brosh and 
Rotter 2009). It also regulates sequence-specific DNA binding by a mechanism that 
is still not well understood (Prives and Hall 1999). The TET domain mediates 
tetramer formation, subsequently providing optimal transcriptional activity (Jeffrey, 
Gorina et al. 1995). Truncations of the Reg domain result in inefficient 
transactivation of genes (McKinney, Mattia et al. 2004). 
 
Regulating p53 levels 
Modes of regulation 
During unstressed conditions, cells have extremely low p53 levels due in part 
to its short half-life (Levine 1997; Marine, Francoz et al. 2006). However, following 
DNA damage, there exists an abundance of mechanisms and networks that are 
responsible for controlling p53 levels. Except for few studies, there is little evidence 
suggesting the control of p53 expression is at the mRNA level (Mosner, 
Mummenbrauer et al. 1995). One study for example suggests that Wig-1, a p53 
target gene, binds 3’ UTR of the p53 mRNA and stabilizes it (Vilborg, Glahder et al. 
2009). However, most data demonstrate that p53 levels are regulated at the protein 
level via direct interactions with other negative regulators or indirectly, via post-
translational modifications. For instance, Cop1, Pirh2, Trim24, Mdm2 and Mdm4 are 
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all reported to attenuate p53 levels. Stress-induced activation of p53 primarily aims 
at disrupting p53 interactions with Mdm2 and Mdm4 (Perry 2010).  
 
Regulation by Mdm2 and Mdm4 
Mdm2 was first discovered as a protein overexpressed in murine tumor cell 
lines (Fakharzadeh, Trusko et al. 1991). Its exact role in oncogenesis remained 
elusive until Mdm2 was coimmunoprecipitated in a complex with p53 and showed it 
can abrogate p53’s transcriptional activity. Mdm2 functions as an E3 ubiquitin ligase 
inhibiting p53 by binding to its TAD and targeting it for proteosomal degradation 
(Figure 2) (Momand, Zambetti et al. 1992; Honda, Tanaka et al. 1997). Mdm2 is 
itself a transcriptional target of p53 creating a negative feedback loop to maintain 
tight p53 levels in the cell (Barak, Juven et al. 1993; Wu, Bayle et al. 1993). 
Mdm4 is another negative regulator of p53 that interacts with Mdm2 to inhibit 
p53. Binding of Mdm4 to Mdm2 stabilizes the later and subsequently leads to lower 
p53 levels in the cell (Gu, Kawai et al. 2002). In addition to p53, Mdm2 ubiquitylates 
Mdm4, and targets it to the nucleus where it is degraded (de Graaf, Little et al. 
2003). Other negative regulators of p53 include Cop1 and Pirh2. Like Mdm2, these 
proteins target p53 for proteosomal degradation, and inhibit p53’s transcriptional 
activity in vitro (Toledo and Wahl 2006). Most recently, Trim24 has been found to 
downregulate p53 levels via E3 ubiquitin ligase activity (Allton, Jain et al. 2009). The 
significance of Cop1, Pirh2 and Trim24 in regulation of p53 in mammalian systems 
is yet to be determined. 
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*Figure 2. Regulation of p53 by Mdm2. Mdm2 uniquitylates p53 and targets it for 
proteosomal degradation. Uninhibited p53 can transactivate cell cycle arrest and 
apoptosis target genes. P53 can transactivate Mdm2 creating a negative feedback 
loop. 
 
*Reprinted by permission from Macmillan Publishers Ltd: Cell Death and Differentiation (2010) 17, 
93–102; doi:10.1038/cdd.2009.68; published online 5 June 2009. Figure 1. 
 
 
 
 
 
 
     13 
Regulation by posttranslational modifications 
In addition to regulation by ubiquitylation, p53 levels can be regulated via 
phosphorylation (Kruse and Gu 2009). Serine 18 and Serine 23 of mouse p53 are 
phosphorylated after DNA damage, or other stresses, by various kinases such as 
ATM, ATR, Chk1 and Chk2 (Appella and Anderson 2001; Kruse and Gu 2009). 
Such phosphorylation of the N-terminus of p53 inhibits Mdm2-p53 and Mdm4-p53 
interactions resulting in stabilization of p53. Moreover, ATM phosphorylates Mdm2 
and Mdm4 at their C-termini leading to their rapid degradation (Khosravi, Maya et 
al. 1999; Chen, Gilkes et al. 2005). This insures rapid accumulation of p53 in the 
cell and induction of cell cycle arrest or apoptosis. Although modifications of p53’s 
Reg domain are thought to be essential, a p53(7KR) mouse with C-terminal lysines 
changed to arginine is phenotypically normal but sensitizes thymocytes to DNA-
damage easier than wildtype p53 (Krummel, Lee et al. 2005). 
 
These studies collectively show that regulation of p53 is not dependent on 
one mechanism or pathway. Instead, various damaging signals can activate either 
of the aforementioned pathways. Negative regulators of p53 can form complexes 
and negatively or positively regulate each other as in the case with Mdm2 and 
Mdm4. The ultimate goal is to activate p53 when the cell detects abnormalities such 
as aberrant proliferation, and at the same time, to maintain low levels of p53 in a 
cell for its survival. 
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Deleterious effects of uninhibited p53 in normal tissues 
Mdm2 and Mdm4 are both indispensible for development and survival of the 
cell and organism. This is supported by the embryonic lethality of deleting Mdm2 or 
Mdm4 in mice (Jones, Roe et al. 1995; Montes de Oca Luna, Wagner et al. 1995; 
Parant, Chavez-Reyes et al. 2001). This lethality is p53-dependent as genetic 
ablation of p53 rescues the Mdm2–/– and Mdm4–/– mice (Jones, Roe et al. 1995; 
Montes de Oca Luna, Wagner et al. 1995; Parant, Chavez-Reyes et al. 2001). 
Notably in these studies, while Mdm2–/– embryos die because of massive apoptosis 
before implantation, Mdm4–/– die at postimplantation at E7.5-E8.5 due to both loss 
of proliferative capacity and apoptosis. Although Mdm2 and Mdm4 are required for 
survival, excessive levels of these proteins are oncogenic and detrimental 
(Ringshausen, O'Shea et al. 2006; Toledo and Wahl 2006; Xiong, Van Pelt et al. 
2007).  
Because of the embryonic lethality of Mdm2–/– mice, understanding the 
physiological role p53 by Mdm2 is not possible (Marine and Lozano 2009). 
Therefore, several studies bypassed this impediment by manipulating the p53-
Mdm2 balance using different genetic strains in mice (Marine, Francoz et al. 2006). 
For instance, Gerard Evan’s laboratory used mice harboring a switchable 
endogenous p53 in an Mdm2–/– background and showed that p53 was stabilized 
and induced either apoptosis or cell cycle arrest (Ringshausen, O'Shea et al. 2006). 
Interestingly, p53 activation was independent of any post-translational modifications 
of p53 or any DNA damage indicating that the major role of Mdm2 is to dampen p53 
levels even during homeostasis to maintain survival of mice (Marine, Francoz et al. 
2006; Marine and Lozano 2009). In other work, p53 elevation due to a hypomorphic 
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Mdm2 allele led to severe lymphoid tissue defects and susceptibility to sublethal 
irradiation (Mendrysa, McElwee et al. 2003).  
 
Although Mdm2+/– and Mdm4+/– mice are normal and viable, their 
hematopoietic tissues are highly sensitive to sublethal irradiation (Terzian, Wang et 
al. 2007). Specifically, haploinsufficiency of Mdm2 or Mdm4 maintains elevated p53 
levels after irradiation which depletes bone marrow cellularitiy (Terzian, Wang et al. 
2007).  Also, Mdm2+/– Mdm4+/– mice suffer from severe p53-dependent 
hematopoietic defects and die shortly after birth (Terzian, Wang et al. 2007). Thus, 
it is important to understand the effect of deregulated Mdm2-p53 balance in the 
bone marrow that is continuously active and cycling throughout the life of an 
organism. 
 
Founding hematopoiesis 
Identification of hematopoietic tissues 
 The aftermath of the atomic bombs in Hiroshima and Nagasaki in 1945 led to 
the observation that the hematopoietic system was very sensitive to radiation 
(Weissman and Shizuru 2008). Particularly, while patients exposed to high radiation 
dosages died shortly afterwards due to toxicity, those exposed to lower levels 
succumbed a few years later to infections or diminishing platelets counts (Domen, 
Wagers et al. 2006). In order to address how radiation could have instigated such 
severe hematopoietic defects, Leon Jacobson and his colleagues started a series of 
radiation experiments on mice in the late 1940’s. The team then rescued the 
irradiation-induced mortality in rodents via shielding the spleen in adult mice and 
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showed that the spleen harbored hematopoietic activity (Jacobson, Marks et al. 
1949). The same group also identified the liver, the leg and the head as other 
organs with hematopoietic potential, and that shielding any of these organs 
increased the survival of mice exposed to lethal irradiation (Jacobson, Simmons et 
al. 1951). Most notably, injecting unirradiated bone marrow or spleen cells into 
lethally irradiated rodents rescues these animals from death (Jacobson, Simmons et 
al. 1951; Nowell, Cole et al. 1956). These studies founded the concept of 
hematopoietic organs and their sensitivity to irradiation. 
 
Spleen: one habitat for hematopoiesis 
 Based on the previously mentioned discoveries, Till and McCulloch (1961) 
examined the homing of the injected bone marrow cells into the lethally irradiated 
mice. The report, published in Radiation Research in 1961, identified the spleen as 
an environment where injected bone marrow cells home to and proliferate (Till and 
McCulloch 1961). Even more, the number of cells injected correlated with the 
number of visible hematopoietic nodules (Till and McCulloch 1961). Within these 
nodules, erythrocytic, grandulocytic and megakaryocytic cells were identified (Till 
and McCulloch 1961).  A few years later, the group also identified lymphoid cells in 
these colonies concluding that intact bone marrows can give rise to all lineages of 
the blood system (Wu, Siminovitch et al. 1968; Wu, Till et al. 1968). 
 
Isolation and characterizing of hematopoietic stem cells 
Dissecting the hierarchy 
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 The current view of the hematopoietic system is its hierarchal structure with 
hematopoietic stem cells at its apex (Figure 3) (Orkin and Zon 2008). Hematopoietic 
stem cells give rise to short-term progenitors that produce more committed 
progenitors, namely common myeloid progenitors (CMP) and common lymphoid 
progenitors (CLP) (Orkin 2000; Orkin and Zon 2008). The latter cells then provide 
the committed precursors, which subsequently differentiate into mature 
hematopoietic cells which are relatively short-lived. Hence, hematopoietic stem cells 
repeat this cycle throughout their lifetime in order to replenish the blood and bone 
marrow with its constituents, while maintaining their ability to self-renew (Orkin and 
Zon 2002; Mikkola and Orkin 2006).  
 
First conception of a hematopoietic stem cell 
In 1956, Dr. E Donnall Thomas performed the first human bone marrow 
transplantation and rescued a 59-year-old leukemia patient (Thomas, Lochte et al. 
1959). This work earned him the Noble Prize in 1990. While the cell of origin 
responsible for saving the patient was obscure, the idea of existence of a cell that 
was responsible to reconstitute all the blood was supported by observations from 
other groups via transplantation experiments in rodents (Barnes and Loutit 1953). 
Then, using a chromosomal marker, a team led by Till discovered that the nodules 
seen in the spleens of injected mice were clones from a single cell (Becker, 
McCulloch et al. 1963). Barnes, in a letter to Lancet’s editor, described these cells 
as “haemopoietic stem-cells” and coined this term (Barnes and Loutit 1967). The 
concept that hematopoietic stem cells have the ability to produce all blood cell 
lineages and self-renew is now widely supported (Weissman 2000).  
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*Figure 3. Hematopoietic hierarchy. Long term hematopoietic stem cells (LT-
HSC) sit at the top of the hierarchy giving rise to progenitors that their progeny 
differentiate and are short lived. 
 
*Modified and reprinted by permission from Elsevier Ltd: Cell 132, 631-644 (February 2008) DOI 
10.1016/j.cell.2008.01.025.  Figure 5. 
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Negative selection markers 
Clinically, bone marrow transplantation became more popular by the late 
1970s (Weissman and Shizuru 2008). Studies then emerged for prospective 
physical isolation of hematopoietic stem cells to aid in better transplantation 
efficiencies. The sole criteria for considering a population enriched for 
hematopoietic stem cells is whether it can more efficiently repopulate all the blood 
cell lineages in transplanted recipients (Weissman and Shizuru 2008). To that end, 
several groups devised a screen for cell-surface markers using flurochrome-
conjugated monoclonal antibodies that select for stem cells or exclude differentiated 
cells. The first monoclonal antibody generated against blood cells recognized 
murine differentiated B cells and their precursors (Coffman and Weissman 1981; 
Coffman and Weissman 1981). With the advancement of fluorescence-activated cell 
sorting (FACS) at that time, cells expressing the differentiated B-lineage marker, 
B220, were sorted and monitored for their potential to form colonies in vitro and in 
vivo. Studies concluded that cells expressing B220 were incapable of forming 
colonies or reconstituting hematopoiesis, in contrast to cells lacking B220 (Coffman 
and Weissman 1981; Muller-Sieburg, Whitlock et al. 1986). With the identification of 
more differentiation lineage markers (Ter119, CD11b/Mac1, CD4, CD8a, Gr-1), it 
became clear that cells expressing lineage committed markers cannot reconstitute 
hematopoiesis and hence should be used for negative selection of hematopoietic 
stem cells from the bone marrow (Muller-Sieburg, Whitlock et al. 1986; Morrison 
and Weissman 1994). Collectively, these markers of negative selection became 
known as Lin–, for “lineage negative”. 
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Positive selection markers 
 After the identification of negative selection markers to enrich for 
hematopoietic stem cells, the search for markers that are expressed on 
hematopoietic stem cells took off. Mouse hematopoietic precursor cells were found 
to have low expression of the cell surface differentiation antigen Thy-1 (Berman and 
Basch 1985). A breakthrough in the enrichment of hematopoietic stem cells, 
however, came from a monoclonal-antibody screen for a putative pre-T hybridoma 
marker (Aihara, Buhring et al. 1986). One antibody, E13 161-7, bound lymphoid 
cells of bone marrow progenitors and thirty Lin– Thy-1lo cells that were also positive 
for the E13 161-7 antibody rescued 50 percent of lethally irradiated mice 
(Spangrude, Heimfeld et al. 1988; Spangrude, Klein et al. 1989). The antigen 
recognized by E13 161-7 antibody was dubbed “stem cell antigen-1” or Sca-1 
(Spangrude, Heimfeld et al. 1988; Spangrude, Klein et al. 1989). The Lin– Thy-1lo 
Sca1+ purified hematopoietic stem cell can differentiate into all lineages 
(Spangrude, Heimfeld et al. 1988). At the same time, bone marrow cells expressing 
c-kit, a known oncogene that encoded a tyrosine kinase receptor, were shown to 
harbor hematopoietic stem cell characteristics by rescuing lethally irradiated mice 
(Okada, Nakauchi et al. 1991; Ikuta and Weissman 1992). 
 
By the mid 1990’s, the hematopoiesis field reached a consensus to use the 
Lin– ckit+ Sca-1+ (hereafter referred to as LKS) population of the adult bone 
marrow as a highly enriched population for hematopoietic stem cells. The LKS 
population contains a subset of long-term hematopoietic stem cells (LT-HSCs), with 
self-renewal capacity, and short-term hematopoietic stem cells (ST-HSCs), or 
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multipotent progenitors. LT-HSCs are capable of long-term (>5 months) 
reconstitution of hematopoiesis when transplanted into irradiated mice, while ST-
HSCs can reconstitute recipients for <2 month as they have limited self-renewal 
capacity (Miller, Dykstra et al. 2008). The journey to decipher markers that 
distinguish LT-HSCs from ST-HSCs began.  
 
Recent advancement in purification of hematopoietic stem cells 
 CD34 and flk2/flt3 can be used to discriminate between LT-HSCs and ST-
HSCs (Papathanasiou, Attema et al. 2009). Specifically, LKS CD34– flk2– and LKS 
CD34+ flk2+ represent LT-HSC and ST-HSC populations, respectively (Osawa, 
Hanada et al. 1996; Christensen and Weissman 2001). More recently, using gene 
expression arrays Morrison’s group identified signaling lymphocyte activation 
molecules family, or SLAM, which regulates the proliferation and activation of 
lymphocytes, to select for LT-HSCs (Howie, Okamoto et al. 2002; Kiel, Yilmaz et al. 
2005). The authors showed that 48% of LKS CD150+ CD48– (LKS-SLAM) cells in 
adult bone marrows were LT-HSCs (Kiel, Yilmaz et al. 2005). Noteworthy, the 
accuracy of using LKS-SLAM for 48% enrichment of LT-HSCs is still subject to 
controversy when compared to side-population/dye exclusion analysis for 
enrichment of hematopoietic stem cells (Weksberg, Chambers et al. 2008). 
However, it is now generally accepted that LKS-SLAM population enriches more for 
LT-HSCs than just using LKS, and constitutes a more rigorous approach for 
hematopoietic stem cell analysis (Wagers 2005; Papathanasiou, Attema et al. 
2009).  
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Developmental journey of hematopoietic stem cells 
Conserved hematopoiesis map 
 The developmental origins and the processes of hematopoiesis are generally 
conserved among vertebrates (Orkin and Zon 2008). Most of our understanding of 
these processes is based on studies that utilize the mouse as a genetic system, and 
to a lesser, but notable, extent from zebrafish studies (Orkin and Zon 2008). Since 
the anatomy of the embryo changes continuously during organogenesis, 
hematopoiesis progresses to different sites (Mikkola and Orkin 2006). The 
anatomical map and timeline of hematopoiesis undertook from embryogenesis to 
adulthood have been successfully drawn (Figure 4). However, the molecular and 
signaling pathways that regulate the trafficking have yet to be determined. 
 
Primitive hematopoiesis 
 The ultimate purpose of hematopoiesis during early embryogenesis is to 
produce red blood cells to transfer oxygen to embryonic tissues for rapid growth 
(Orkin and Zon 2008). This phase of hematopoiesis is termed “primitive” and takes 
place in the yolk sac at around embryonic day (E) 7.0 until E8.25 in the mouse 
embryo (Palis, McGrath et al. 1995; Palis, Robertson et al. 1999). Red blood cells 
from primitive hematopoiesis retain their nucleus and are relatively large cells (Palis, 
Robertson et al. 1999; Ferkowicz, Starr et al. 2003). The origin of red blood cells 
precursors of primitive hematopoiesis has been a matter of controversy in the field 
since the early 1900’s. In 1917, Florence Sabin suggested that the hemangioblast, 
a mesodermal  precursor in the yolk sac, can give rise to blood and endothelial cells  
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Figure 4. Anatomical distribution of hematopoiesis in the mouse. Primitive 
hematopoiesis starts in the yolk sac (YS) at about E7.5 followed by definitive 
hematopoiesis. The aorta-gonad-mesonephros accommodate hematopoiesis at 
about E10. Placenta (plac.) and fetal liver (FL) are hematopoietic tissues as early as 
E11. FL becomes major organ of expansion of HSC until bone marrow can 
accommodate hematopoiesis at about E16 and throughout adulthood. Day 0 
designates first day of pregnancy. Mice gestation period is approximately 20 days. 
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and is the origin of primitive hematopoiesis. Interestingly, some studies indicate that 
although primitive hematopoiesis is in the yolk sac, red blood cell precursors 
develop before they migrate to the yolk sac (Palis, Chan et al. 2001; Palis and 
Yoder 2001). This refutes the postulation that the hemangioblast is in the yolk sac, 
but not that a hemangioblast actually exists (Mikkola and Orkin 2006).  
Hematopoietic cells are reported to be “budding” from endothelial tissues 
proposing that endothelial cells give rise to primitive hematopoiesis (Garcia-Porrero, 
Godin et al. 1995; Zovein, Hofmann et al. 2008). With the advancement of live 
imaging, endothelial cells are captured in bona fide time giving rise to blood cells 
(Eilken, Nishikawa et al. 2009). Although these data support the concept that 
endothelial cells give rise to blood cells, it does not prove that endothelial and blood 
cells have a common precursor, i.e. the hemangioblast. Also, the live imaging 
studies do not eliminate the possibility that other cells may still give rise to 
hematopoietic precursors (Eilken, Nishikawa et al. 2009).  
 
Definitive hematopoiesis 
 The short primitive hematopoiesis period is followed by what is known as 
“definitive” hematopoiesis. In this process, all lineages (erythroid, myeloid and 
lymphpoid) are generated (Lancrin, Sroczynska et al. 2009). After it initiates in the 
yolk sac at E8.25, definitive hematopoiesis proceeds in the aorta-gonad 
mesonephros (AGM) at around E10, where the activity of hematopoietic stem cells 
increases by E11 (Medvinsky, Samoylina et al. 1993). Although the placenta acts as 
a hematopoietic organ as early as E9 in mice, mature hematopoietic stem cells are 
not found in the placenta until E10.5-E11 (Alvarez-Silva, Belo-Diabangouaya et al. 
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2003; Ottersbach and Dzierzak 2005). Hematopoietic stem cells in the placenta 
expand rapidly, and without differentiation, becoming 15 fold more than 
hematopoietic stem cells counts in the yolk sac or AGM (Gekas, Dieterlen-Lievre et 
al. 2005). The origin of placental hematopoietic stem cells is still controversial. 
Some thoughts indicate that these cells are generated in situ, while others indicate 
that these cells could have colonized in the placenta via circulation (Orkin and Zon 
2002; Mikkola and Orkin 2006). At some point between E11 and E12, hematopoietic 
stem cells start expressing CD45 and Sca-1 markers, a hallmark of a more mature 
state (North, de Bruijn et al. 2002; Matsubara, Iwama et al. 2005). 
 
Hematopoiesis in the fetal liver 
 As early as E10, hematopoietic activity becomes apparent in the fetal liver 
and hematopoietic stem cells start populating the liver at E11.5 (Jordan, McKearn et 
al. 1990; Orkin and Zon 2002). At E12.5, the fetal liver becomes the major organ for 
expansion and differentiation of hematopoietic stem cells, and at approximately 
E16, this activity starts to decline (Morrison, Hemmati et al. 1995; Ema and 
Nakauchi 2000). Unlike the yolk sac, AGM and placenta, the fetal liver 
hematopoietic compartment is quite rich with hematopoietic progenitors and lineage 
positive cells which significantly contributed to establishing the hierarchal structure 
of the hematopoietic system (Figure 3). The robust expansion of hematopoietic 
stem cells in the fetal liver is linked to signals from the fetal liver microenvironment 
that promote symmetric self-renewing division. However, identity of key cell types of 
the fetal liver microenvironment remains obscure and is under investigation. 
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Establishment of the bone marrow 
During the expansion of the hematopoietic compartment in the fetal liver at 
E12.5, the skeletal system is being established to accommodate hematopoiesis in 
the bone during late gestation and throughout the life of the organism (Collins, 
Olsen et al. 2005). Hematopoietic stem cells start seeding the bone at around E17.5 
although other hematopoietic cells start migrating to the bone as early as E15.5 
(Christensen, Wright et al. 2004). Little is known about the signals that the fetal 
hematopoietic stem cells receive to initiate their migration to the bone, however the 
chemokine stromal cell-derived factor-1 (Sdf1) is a key element (Ara, Tokoyoda et 
al. 2003). While in the bone, hematopoietic stem cells establish the marrow and 
finalize the hierarchal structure of the hematopoietic compartment.  
 
The switch to adult-state hematopoietic stem cells 
While embryonic hematopoietic stem cells are highly cycling and expanding, 
adult hematopoietic stem cells are more dormant (Bowie, McKnight et al. 2006). 
This is concomitant with changes in expression of cell surface markers. For 
instance, embryonic hematopoietic stem cells express the lineage commitment 
markers Mac-1 (monocytic/macrophage marker) and Aa4.1 (B-cell marker), while 
adult hematopoietic stem cells do not (Jordan, McKearn et al. 1990; Morrison, 
Hemmati et al. 1995; Rebel, Miller et al. 1996).  This switch from embryonic to adult 
hematopoietic stem cells occur at or around three weeks postnatally in mice and is 
marked by decreased cycling and loss of expression of Mac-1 and Aa4.1 (Bowie, 
McKnight et al. 2006; Bowie, Kent et al. 2007). The bone marrow then leads as the 
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major niche for sustaining hematopoiesis and accommodating hematopoietic stem 
cells throughout adulthood.  
 
The hematopoietic niche 
The niche hypothesis 
 A team led by Wolf (1967) transplanted bone marrows and spleens into 
irradiated mice and counted the various colonies that formed in anatomically distinct 
organs (Curry, Trentin et al. 1967). They later observed erythropoietic colonies in 
the spleen, while the bone marrow colonies were predominantly myelomonocytic 
(Wolf and Trentin 1970). Their experiments correlated the environment where 
hematopoietic cells were growing with the identity, or fate, of their progeny. A few 
years later, Schofield coined the term “niche” (to nest in French) to describe the 
environment where hematopoietic stem cells home to and reside (Schofield 1978). 
Schofield (1978) was the first to propose that the role of the bone marrow niche was 
to maintain the proliferative capacity of hematopoietic stem cells and inhibit their 
maturation. 
 
Bone marrow enodosteal niche 
 As previously mentioned, the embryonic niche for hematopoietic stem cells is 
anatomically distinct. But very little is known about the cellular compartments in 
these tissues that govern the hematopoietic stem cell communication with the niche 
during embryogenesis. On the other hand, more is known about the underlying 
regions involved in maintenance of hematopoietic stem cells in the adult bone 
marrow. Despite various discrepancies in the literature due to technical issues, two 
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distinct environments have been identified: the endosteal and the vascular bone 
marrow niche (Wilson and Trumpp 2006). 
 The endosteum is the cellular lining that separates the bone from the bone 
marrow, and is constituted of osteoblasts, osteoclasts and stromal fibroblasts 
(Wilson and Trumpp 2006). Hematopoietic stem cells are found in close association 
with the endosteum, while more differentiated cells are in the central region of the 
bone marrow (Zhang, Niu et al. 2003; Kiel, Yilmaz et al. 2005). Direct evidence 
supporting the endosteal origin of the hematopoietic niche came from David 
Scadden’s and Linhend Li’s laboratories. Their studies unequivocally demonstrate 
that altering the abundance of osteoblasts via modulating levels of parathyroid 
hormone (PTH) or bone morphogenetic protein (BMP), regulators of bone formation 
and resorption, dictate the hematopoietic stem cell pool number and activity (Calvi, 
Adams et al. 2003; Zhang, Niu et al. 2003). 
 
The vascular niche 
 Since hematopoietic stem cells may also originate from endothelial cells, it is 
not surprising that the vasculature constitutes another niche for hematopoietic stem 
cells (Wilson and Trumpp 2006). The vasculature niche of the bone marrow, which 
is formed by the bone marrow sinusoidal endothelial cells (BMECs), is functionally 
and phenotypically different from the microvasculature endothelial cells of other 
organs (Kopp, Avecilla et al. 2005; Wilson and Trumpp 2006). BMECs secrete 
cytokines and express adhesion molecules that are required for hematopoietic stem 
cell engraftment, homing and mobilization (Sipkins, Wei et al. 2005).  
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Collaboration of endosteal and vascular niche 
The endosteal and vascular bone marrow niche are not two independent 
environments. These two niches cooperate to support self-renewal capabilities and 
inhibit differentiation of hematopoietic stem cells (Wilson and Trumpp 2006). In fact, 
it is estimated that quiescent hematopoietic stem cells reside in close proximity with 
osteoblasts of the endosteal niche (Calvi, Adams et al. 2003; Scadden 2006). As 
soon as these cells are required to proliferate and reconstitute hematopoiesis, they 
detach from the osteoblastic lining and migrate towards the vasculature zone which 
is located in the center of the bone marrow (Kopp, Avecilla et al. 2005). Since 
ablation of osteoblasts activates extramedullary hematopoiesis (Visnjic, Kalajzic et 
al. 2004), the vascular niche is not sufficient to support hematopoiesis in bone 
marrows and is considered a “secondary niche, requiring an influx of hematopoietic 
stem cells from the primary endosteal niches” (Wilson and Trumpp 2006). 
 
 
Oxidative nature of the hematopoietic compartment 
Hematopoietic stem cell and Reactive Oxygen Species distribution 
ROS are generated by intrinsic or extrinsic sources, such as metabolism and 
ionizing radiation, respectively, and can cause DNA damage (Lombard, Chua et al. 
2005; Naka, Muraguchi et al. 2008). Hence, the oxidative nature of the 
hematopoietic niche may dictate the level of protection it can provide to 
hematopoietic stem cells. The osteoblastic lining of the bone is considered hypoxic 
and hence provides a protective environment to harbor hematopoietic stem cells 
(Naka, Muraguchi et al. 2008). In humans, bone marrows are thought to be in 
hypoxic conditions, but not enough to initiate a hypoxic molecular response 
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(Harrison, Rameshwar et al. 2002; Eliasson and Jonsson 2009). Also, slow cycling 
hematopoietic stem cells are associated with hypoxic regions of capillaries 
suggesting that low ROS maintain quiescence and self-renewal (Suda, Arai et al. 
2005; Kubota, Takubo et al. 2008). Collectively, these studies suggest that 
hematopoietic stem cells are located in a low-oxygen milieu of the bone marrow – 
specifically associated with osteoblastic niche – supporting their long-term 
hematopoietic activity and protecting the cells from ROS-related oxidative stress. 
 
ROS in hematopoietic stem cells   
 The earliest correlative studies of ROS and hematopoietic stem cell 
maintenance came from the Atm–/– mouse model (Ito, Hirao et al. 2004). Briefly, 
Atm–/– mice suffered from hematopoietic defects that were manifested late in life 
(Ito, Hirao et al. 2004). Atm loss led to significantly elevated ROS levels in the 
hematopoietic compartment, ultimately leading to loss of hematopoietic stem cell 
self-renewal capability (Ito, Hirao et al. 2004). Other studies used ROS levels to 
distinguish among various HSC self-renewal capacities (Jang and Sharkis 2007). 
Specifically, HSCs with lower ROS content can engraft irradiated recipients better 
than HSCs with higher ROS (Jang and Sharkis 2007). Other pathways such as Bmi-
1, p38-Mapk and FoxO can regulate ROS levels in hematopoietic stem cells and 
influence their activity (Ito, Hirao et al. 2006; Tothova, Kollipara et al. 2007; Liu, Cao 
et al. 2009). Conclusively then, disrupting ROS levels leads to hematopoietic stem 
cell exhaustion and depletion. Yet, the downstream targets of ROS and how these 
targets could affect hematopoiesis remain unknown. 
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Mdm2-p53 pathway in hematopoietic stem cells 
p53 loss increases hematopoietic stem cell cycling 
 Since hematopoietic stem cells are subject to ROS-induced DNA damage, 
and since p53 is activated due to stress, it is important to delineate the role of the 
p53 pathway in hematopoietic stem cells and their maintenance. Loss of p53 in 
hematopoietic stem cells increases their cycling and expands this population (Liu, 
Elf et al. 2009). This may ultimately lead to mutations and genetic aberrations, and 
consequently leukemias (Akala, Park et al. 2008; Liu, Elf et al. 2009) 
 
Mdm2–/– p53515C/515C: a good model to address p53 role in hematopoiesis 
As previously discussed, the early embryonic lethality of Mdm2-null mice 
impedes the study of the effects of disrupting the Mdm2-p53 balance on 
hematopoiesis. Fortunately, Mdm2–/– mice can be rescued using a hypomorphic 
allele of p53 (p53515C) (Liu, Terzian et al. 2007). However, Mdm2–/– p53515C/515C mice 
suffer from acellular bone marrows and die shortly after birth (Liu, Terzian et al. 
2007). Intriguingly, Mdm2–/– p53515C/515C pups are born morphologically 
indistinguishable from control Mdm2+/– p53515C/515C littermates despite nullizygosity 
of Mdm2. Based on this observation, we asked several questions. First, why did 
hematopoiesis proceed during embryogenesis compared to neonatal development 
in absence of Mdm2? Also, why did Mdm2–/– p53515C/515C mice exhibit a severe 
phenotype after birth? Is p53R172P (the protein encoded by p53515C) stable and 
active during embryogenesis? How does the disruption of Mdm2-p53 pathway 
influence the hematopoietic stem cell and progenitor pools? 
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In this dissertation we provide evidence that hematopoietic stem/progenitor 
cells are highly sensitive to elevated ROS-induced p53R172P levels. p53R172P 
stimulates ROS production via activation of set of redox-related genes collectively 
known as p53-induced-genes. In the absence of Mdm2, this creates a positive 
feedback loop to maintain elevated p53 levels. Growing Mdm2–/– p53515C/515C 
hematopoietic stem cells at low oxygen conditions allowed normal expansion of this 
population. Moreover, genetic ablation of p16 increases cycling in the hematopoietic 
compartment, expands the hematopoietic stem cell population and their progenitors, 
and increases survival. On the other hand, p21 deletion did not affect the 
hematopoietic compartment. p53R172P stability exerted several effects on the 
hematopoietic niche leading to increased osteoblastic activity. We conclude that 
although p53 is required to inhibit tumorigenesis, uncontrolled p53 levels can be 
detrimental to the hematopoietic compartment and thus to the organism. Most 
importantly, Mdm2 is constantly and evolutionarily required to control p53 levels in 
bone marrows to insure the survival of the organism. 
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RESULTS 
 
Establishing and characterizing the cohort 
Genetic crosses 
In order to make Mdm2–/– p53515C/515C mice, we followed the genetic scheme 
shown in Figure 5. Briefly, we used previously generated Mdm2+/– and p53515C/+ 
mice (Montes de Oca Luna, Wagner et al. 1995; Liu, Parant et al. 2004) that were 
87.5% C57BL/6 and already housed in our animal facility. The first step was to 
backcross these mice into a higher C57BL/6 background to avoid immune 
rejections in case transplantation experiments were warranted during our studies. 
We performed Polymerase Chain Reaction (PCR) using previously published 
primers in order to distinguish the different Mdm2 and p53515C alleles (Montes de 
Oca Luna, Wagner et al. 1995; Liu, Parant et al. 2004). Mdm2+/– p53515C/+ were 
generated by breeding Mdm2+/– and p53515C/+ mice to each other. Mdm2+/– p53515C/+ 
were bred to p53515C/515C to get the Mdm2+/– p53515C/515C mouse colony. Finally, 
Mdm2+/– p53515C/515C mice were mated to each other to generate the Mdm2–/– 
p53515C/515C study group, and Mdm2+/– p53515C/515C and Mdm2+/+ p53515C/515C control 
groups all from one cross in a 1:2:1 ratio, respectively.  
  
Survival curve 
Out of 106 pups born from intercrossing Mdm2+/– p53515C/515C mice, 26, 27 
and 53 were Mdm2–/– p53515C/515C, Mdm2+/+ p53515C/515C and Mdm2+/– p53515C/515C, 
respectively (Table 1). Hence, Mdm2–/– p53515C/515C mice were born at normal 
Mendelian ratios and confirmed previously published work (Liu, Terzian et al. 2007).  
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Mdm2+/–          x      wildtype                        p53515C/+         x      wildtype 
   (~87.5% C57/B6)        (100% C57/B6)                 (~87.5% C57/B6)        (100% C57/B6) 
 
 
 
          ½ Mdm2+/–                                                           ½ p53515C/+ 
        (~94% C57/B6)                                                      (~94% C57/B6) 
 
 
            
                                        ¼ Mdm2+/– p53515C/+    x     p53515C/515C 
 
 
 
 
  Mdm2+/– p53515C/515C     x         ¼ Mdm2+/– p53515C/515C 
 
 
 
 
                        ½ Mdm2+/– p53515C/515C 
        ¼ Mdm2+/+ p53515C/515C 
        ¼ Mdm2–/– p53515C/515C 
 
 
Figure 5. Genetic scheme Backcrossing of Mdm2+/– and p53515C/+ into a C57/B6 
background followed by generation of Mdm2+/– p53515C/515C. Expected ratios are 
noted next to genotypes.  
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Table 1. Expected ratios and number of mice born of each genotype after crossing 
Mdm2+/– p53515C/515C mice to each other.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Genotype Mdm2+/+ 
p53515C/515C 
Mdm2+/– 
p53515C/515C 
Mdm2–/– 
p53515C/515C 
Total 
Ratio 
Expected 
1/4 1/2 1/4 1/1 
Number 
expected 
26.5 53 26.5 106 
At birth 27 53 26 106 
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Although it was previously  reported  that  all  Mdm2–/– p53515C/515C  die  within  two 
weeks  after birth (Liu, Terzian et al. 2007), a detailed survival curve was still 
lacking. To that end, we monitored litters from pregnant females at least twice on 
daily basis. The day a litter was born was noted as postnatal day (P) 0. The number 
of pups at birth was counted twice a day, and tissues of dead pups were collected 
for genotyping. 95% of Mdm2+/– p53515C/515C and 87% of Mdm2+/+ p53515C/515C pups 
survived until weaning age and were used for future breeding experiments (Figure 
6). On the other hand, 65% of Mdm2–/– p53515C/515C pups were dead by P2 (Figure 
6). Of the Mdm2–/– p53515C/515C pups surviving until P2, none died between P3 and 
P10. Between P11 and P13, all Mdm2–/– p53515C/515C pups died (Figure 6). 
 
Growth retardation 
Mdm2–/– p53515C/515C pups were indistinguishable from their control 
littermates at birth (Figure 7a). We then monitored the mice for any obvious 
changes in size or morphology. At approximately P6, Mdm2–/– p53515C/515C mice 
started showing signs of growth retardation (Figure 7a). By P10, all Mdm2–/– 
p53515C/515C pups were easily discernable from their control littermates by their 
smaller size (Liu, Terzian et al. 2007). No notable differences were observed 
between Mdm2+/– p53515C/515C and Mdm2+/+ p53515C/515C littermates. Necropsy on 6 
day old pups showed significantly smaller and pale spleens in Mdm2–/– p53515C/515C 
pups as compared to spleens of control Mdm2+/– p53515C/515C pups (Figure 7b). 
Although Mdm2–/– p53515C/515C pups were previously reported to have hematopoietic 
defects (Liu, Terzian et al. 2007), detailed analysis of this phenotype and the 
molecular changes at various time points remained to be elucidated. 
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Figure 6. Kaplan-Meier survival curves of Mdm2–/– p53515C/515C (n=26), Mdm2+/– 
p53515C/515C  (n=53) and Mdm2+/+ p53515C/515C  (n=27) mice. Mdm2–/– p53515C/515C 
pups had a significantly (p<0.0001) shorter survival curve compared to control 
Mdm2+/– p53515C/515C and Mdm2+/+ p53515C/515C littermates. Notably, a high 
percentage of Mdm2–/– p53515C/515C pups died within the first two days after birth.  
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         a.  
                                         P0                               P6                                            b.         
 
 
 
 
 
 
 
 
 
 
Figure 7. Snapshots of P0 and P6 pups, and P6 spleens. (a) Mdm2–/–p53515C/515C 
pups are indistinguishable at P0 but start showing signs of growth retardation at P6. 
(b) Spleens of Mdm2–/–p53515C/515C mice at P6 are smaller and pale. 
 
 
 
 
 
Mdm2–/–
p53515C/515C   Mdm2+/–p53515C/515C   Mdm2–/–p53515C/515C  
Mdm2–/–
p53515C/515C  Mdm2+/–p53515C/515C  
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Hematopoiesis during embryogenesis and postnatally 
Normal histology of fetal livers and embryonic bone marrows 
Since Mdm2–/– p53515C/515C pups had no observable abnormalities at P0, we 
anticipated hematopoiesis was normal during embryogenesis. As previously 
mentioned, the fetal liver is the major hematopoietic organ between E12.5 and 
E15.5 until hematopoiesis migrates to the bone marrow at late embryogenesis 
(Mikkola and Orkin 2006). Hence, we sacrificed pregnant females at E14.5 and 
E18.5 to examine these two processes. Embryonic tissues were stained with 
hematoxylin and eosin (H&E) for histological analysis. Mdm2–/– p53515C/515C fetal 
livers at E14.5, and bone marrows at E18.5 had normal cellularity and no 
histologically detectable hematopoietic abnormalities (Figure 8).  
 
Acellular postnatal bone marrows 
Mdm2–/– p53515C/515C pups started showing signs of growth retardation at 
approximately P6. We therefore sacrificed neonates at P6, P8, and P10 for careful 
examination of their bone marrows. By P6, bone marrow cellularity of Mdm2–/– 
p53515C/515C mice dropped to approximately 70% and by P10, these mice had less 
than 10% cellularity compared to control littermates (Figure 8). No notable defects 
were observed for bone marrow cellularity of control Mdm2+/– p53515C/515C mice at all 
time points examined. Previously, our lab also showed that the peripheral blood 
cellularity of Mdm2–/– p53515C/515C mice is severely low at P11 (Liu, Terzian et al. 
2007). Hence, loss of Mdm2 depletes the hematopoietic compartment in the bone 
marrows and in the peripheral blood postnatally. In order to address whether  this is  
a p53- dependent   phenotype, we  generated Mdm2–/– p53515C/–  mice.  These mice 
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Figure 8. Mdm2–/– p53515C/515C mice die postnatally due to hematopoietic 
failure. Representative H&E staining of fetal livers (FL) at E14.5 and bone marrows 
(BM) at E18.5 P6, P8 and P10 from Mdm2+/– p53515C/515C (left) and Mdm2–/– 
p53515C/515C mice (right). Scale bar is 200µm. 
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were viable and had no obvious defects as previously reported (Liu, Terzian et al. 
2007). Mdm2–/– p53515C/– males suffered only from atrophic testis and males were 
infertile with no notable hematopoietic defects (Liu, Terzian et al. 2007). These 
experiments confirmed that the hematopoietic defect observed in Mdm2–/– 
p53515C/515C was p53-dependent and was manifested at postnatal time points.  
  
p53R172P stability and activity in the hematopoietic compartment 
Elevated p53R172P in bone marrows, but not fetal livers 
p53515C encodes p53R172P protein. Since Mdm2 targets p53 for degradation 
(Haupt, Maya et al. 1997; Honda, Tanaka et al. 1997), we performed 
immunohistochemisty (IHC) on hematopoietic tissues at various time points to 
investigate p53R172P levels in moribund and control mice. E14.5 fetal livers of 
Mdm2+/– p53515C/515C (control) and Mdm2–/– p53515C/515C mice had very low levels of 
p53R172P staining and were indistinguishable (Figure 9). On the other hand, bone 
marrow cells of Mdm2–/– p53515C/515C mice had elevated p53R172P staining at 
E18.5, P6, P8 and P10. Control Mdm2+/– p53515C/515C littermates were negative for 
p53R172P at all time points except for a few p53R172P positively stained cells 
(Figure 9). Hence, high p53R172P levels correlated with decreased bone marrow 
cellularity in Mdm2–/– p53515C/515C mice postnatally.  
 
Increased p53R172P transcriptional activity postnatally 
E14.5 fetal livers showed normal histology and no p53R172P staining 
(Figures 8 and 9). Also, P6 moribund mice  were  visually  discernable from control  
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Figure 9. p53R172P Immunohistochemical staining. Paraffin-embedded sections 
of E14.5 fetal livers, and E18.5, P6, P8 and P10 bone marrows from Mdm2+/– 
p53515C/515C (left) and Mdm2–/– p53515C/515C (right) were stained for p53R172P and 
counterstained with hematoxylin. Scale bar is 50µm. 
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mice, and had stable p53R172P levels (Figure 7a). Most importantly, P6 bone 
marrows still retained 60-70% bone marrow cellularity (Figure 8) providing us with 
enough cells for mechanistic studies. Hence, we chose E14.5 fetal livers and P6 
bone marrows as representative time points for detailed molecular characterization 
of the embryonic and neonatal phenotypes, respectively. We used Real Time 
reverse transcriptase-PCR (RT-PCR) to look for changes in mRNA levels of known 
p53 target genes. 
We first isolated RNA from whole fetal livers at E14.5 and examined cell 
cycle arrest targets of p53: p21 and Ccng. In fetal livers, differences in p21 (p=0.23) 
and Ccng (0.34) levels were statistically insignificant between Mdm2–/– p53515C/515C 
and control Mdm2+/– p53515C/515C (Figure 10a). One Mdm2–/– p53515C/515C fetal liver 
was 15 fold higher but this outlier did not affect the statistical significance (Figure 
10a). We also examined the apoptosis targets of p53 and found no differences in 
induction of Noxa (p=0.81), Perp (p=0.86) or Puma (p=0.67) in Mdm2+/– p53515C/515C 
compared to Mdm2–/– p53515C/515C mice (Figure 10a). On the other hand, all Mdm2–/– 
p53515C/515C whole bone marrows at P6 had dramatic and significant induction of 
p53 cell cycle targets Ccng (9 fold) and p21 (43 fold) compared to control Mdm2+/– 
p53515C/515C littermates (Figure 10b). As for apoptotic targets, Perp levels were the 
same in all mice (Figure 10b). However, Puma and Noxa levels were consistently 
two fold higher in Mdm2–/– p53515C/515C moribund mice than in Mdm2+/– p53515C/515C 
mice (p<0.02) (Figure 10b).  
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a.  
 
 
 
 
 
 
 
 
 
b.  
 
 
 
 
 
 
 
Figure 10. p53R172P transcriptional activity induces cell cycle arrest genes 
and to a lesser extent apoptosis genes in postnatal bone marrows. Real-Time 
PCR results from E14.5 whole fetal liver (WFL) cells (a) and P6 whole bone marrow 
(WBM) cells (b) on p53 cell cycle arrest (Ccng1 and p21) and apoptosis (Perp, 
Puma and Noxa) targets. All levels were normalized to Gapdh. Error bars represent 
standard error of the mean. 
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Examining cycling, senescence and apoptosis 
Decreased cell cycling in postnatal bone marrows, but not fetal livers 
To investigate the cell cycle pattern in fetal livers and postnatal bone 
marrows, we fixed cells from these tissues and analyzed their DNA content with 
propidium iodide staining. As expected based on normal histological analysis and 
negative p53R172P staining, cell cycle patterns of E14.5 fetal livers between 
Mdm2–/– p53515C/515C and Mdm2+/– p53515C/515C littermates were indistinguishable 
(Figure 11a). Specifically, 53.1%, 27.7% and 15.7% of whole fetal liver cells in 
Mdm2–/– p53515C/515C embryos were in G1, S, G2/M phase, respectively, similar to 
52.7%, 27.0% and 16.2% in control Mdm2+/– p53515C/515C littermates (Figure 11a). 
The fraction of cells in subG1 was less than 2% in both genotypes (Figure 11a).  
P6 bone marrows, however, showed significant differences between the two 
genotypes. Less than 6.5% of Mdm2–/– p53515C/515C bone marrow cells were in S 
phase compared to 22% for control littermates (Figure 11b). Mdm2–/– p53515C/515C 
neonates had 7.1% of cells in the G2/M phase compared to 12.6% in Mdm2+/– 
p53515C/515C littermates (Figure 11b). A significant percentage (14.8%) of Mdm2–/– 
p53515C/515C bone marrow cells as compared to <1.1% of control bone marrow cells 
were in subG1 fraction suggesting cell death as another mechanism of depleting the 
cellular compartment (p=0.03) (Figure 11b).  Among the 6 Mdm2–/– p53515C/515C 
analyzed at P6, three pups had subG1 fractions >14% and the other three had 
subG1 populations between 2% and 4%. Since all Mdm2+/– p53515C/515C mice had 
subG1 levels of less than 1.6%, we attained statistical significance. 
 
 
     46 
 
 
a. 
 
 
 
 
 
 
 
 
b. 
 
 
 
 
 
 
 
Figure 11. Induction of cell cycle arrest and cell death in postnatal bone 
marrows. Cell cycle analysis of E14.5 whole fetal livers (WFL) (a) and P6 whole 
bone marrow (WBM) (b) using propidium iodide on fixed cells of these tissues. Error 
bars represent standard error of the mean. 
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Caspase-3 and AnnexinV are not expressed in Mdm2–/– p53515C/515C bone 
marrows 
Since Puma and Noxa were elevated in Mdm2–/– p53515C/515C P6 bone 
marrows, and since 14% of these cells were in subG1, we investigated apoptosis as 
a mechanism for depleting hematopoiesis. The caspase-3 pathway is usually 
activated in response to p53 dependent apoptosis (Fridman and Lowe 2003). We 
performed IHC in order to assay for cleaved caspase-3 in postnatal bone marrows 
at P6 and P8 (Figure 12). Except for a few positive cells, caspase-3 staining was 
negative in all bone marrows at these time points (Figure 12).  
We then used AnnexinV staining as an alternative method to look for 
apoptosis with flow cytometry. E14.5 whole fetal livers of both Mdm2–/– p53515C/515C  
and Mdm2+/– p53515C/515C had less than 1.6% (p=0.71) of cells expressing AnnexinV 
(Figure 13a).  Also for P6 whole bone marrows there was no statistical difference 
between pups of the two genotypes for AnnexinV staining (Figure 13b). Hence, 
although cell death is occurring, the standard markers for apoptosis are not positive 
suggesting an alternative mechanism of cell death. 
 
Increased senescence markers in Mdm2–/– p53515C/515C P6 bone marrows. 
p53R172P activates p21 which can induce senescence (Noda, Ning et al. 
1994; Cosme-Blanco, Shen et al. 2007; Post, Quintas-Cardama et al. 2009). We 
hypothesized that Mdm2–/– p53515C/515C bone marrows in early postnatal 
development may also exhibit a senescent phenotype. Accordingly, in addition to 
p21 which was 43 fold higher than controls (Figure 10b), we examined expression 
levels of known senescent markers: Dcr2, p15,  p16, Dec1 and Pml  using  RT-PCR  
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Figure 12. Absence of cleaved caspase-3 staining in P6 and P8 Mdm2–/– 
p53515C/515C bone marrows. Cleaved caspase-3 immunohistochemical staining on 
paraffin embedded bone marrows of Mdm2+/– p53515C/515C (left) and Mdm2–/– 
p53515C/515C (right) at P6 and P8. Irradiated wildtype thymus was used as a positive 
control for cleaved caspase-3 staining. Scale bar is 50µm. 
 
 
 
 
 
 
 
     49 
 
 
  a. 
 
 
 
 
 
 
 
  b. 
 
 
 
 
 
 
 
Figure 13. No statistically significant difference in AnnexinV expression in 
fetal livers and postnatal bone marrows. (a) E14.5 Whole fetal liver (WFL) cells 
and (b) P6 whole bone marrow (WBM) cells were stained with AnnexinV and 
analyzed with flow cytometry. Error bars represent standard error of the mean. n= 
number of mice examined. 
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in E14.5 fetal livers and P6 bone marrows (Collado, Gil et al. 2005; Collado and 
Serrano 2006). Expression levels of these genes in E14.5 whole fetal liver cells 
were the same between Mdm2–/– p53515C/515C embryos and controls (Figure 14a). 
However, in addition to p21, Dcr2 (17 fold) and p15 (11 fold) were highly elevated in 
postnatal bone marrows of Mdm2–/– p53515C/515C mice as compared to controls, while 
Dec1, p16 and Pml mRNA levels did not change (Figure 14b). This indicates that 
senescence could be another pathway activated by p53R172P to inhibit 
hematopoiesis. 
 
p21 deletion extends lifespan of Mdm2–/– p53515C/515C mice 
p21 expression levels were the highest in Mdm2–/– p53515C/515C bone marrows 
among all genes tested at P6  (Figure 10b). Also, p21 maintains quiescence in 
HSCs (Cheng, Rodrigues et al. 2000). Hence, we investigated whether p21 deletion 
might rescue hematopoiesis by increasing proliferation and alleviating senescence 
of bone marrows. Contrary to our expectations, p21 deletion did not rescue bone 
marrow cellularity (Figure 15b). However, the median age and life expectancy were 
longer for these mice indicating a partial rescue of postnatal lethality (Figure 15a). 
Increased survival may be due to effects on other tissues as Mdm2–/– p53515C/515C 
mice also suffer from multiple other defects (Liu, Terzian et al. 2007).  
 
Characterization of hematopoietic stem cells and progenitors  
A major defect in HSC and CLP/CMP populations. 
HSCs are responsible for replenishing the cellular compartment of the blood 
(Weissman 2000).  Since  Mdm2–/–  p53515C/515C bone  marrows  reflect  absence  of  
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Figure 14. Increased senescence markers in bone marrows but not fetal livers 
of Mdm2–/– p53515C/515C mice. Expression levels of senescence markers at (a) 
E14.5 of whole fetal liver (WFL) and (b) P6 of whole bone marrow (WBM) RNA was 
measured by Real Time RT-PCR and was normalized to Gapdh levels. Error bars 
represent standard error of the mean. 
 
 
 
     52 
 
  
 
 
a.  
 
 
 
 
 
 
 
 b.  
 
 
 
 
 
 
 
 
 
 
 
Figure 15. p21 deletion extends survival of Mdm2–/– p53515C/515C mice without 
rescuing bone marrow cellularity. (a) Kaplan-Meier survival curve of Mdm2–/– 
p53515C/515C p21–/– mice compared to other genotypes. Number of mice indicated 
between parenthesis. (b) H&E of P12 bone marrow of Mdm2–/– p53515C/515C p21–/– 
mouse. Scale bar is 200µm. 
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sustainable hematopoiesis, we hypothesized a defect in the HSC and progenitor 
populations. We therefore examined Lin– ckit+ Sca1+ (LKS) and Lin– ckit+ Sca1–
/low cell populations that  represent  HSCs  and  common  lymphoid and myeloid 
progenitors(CLP/CMP), respectively, at different time points throughout 
development (Morrison and Weissman 1994; Weissman and Shizuru 2008). The 
gating strategy for analyzing these populations is depicted in Figure 16. 
E14.5 fetal livers of Mdm2–/– p53515C/515C and Mdm2+/– p53515C/515C mice 
had normal LKS cell populations (0.236% and 0.24%) for Mdm2+/– p53515C/515C and 
Mdm2–/– p53515C/515C embryos, respectively, and normal CLP/CMP populations 
(5.26% and 5.58%) for Mdm2+/– p53515C/515C and Mdm2–/– p53515C/515C embryos, 
respectively (Figures 17a-b). This was expected given the normal histology, 
absence of p53R172P stability, and normal cell cycle pattern of fetal livers at E14.5. 
Unexpectadly, E18.5 bone marrows of Mdm2–/– p53515C/515C embryos showed 
significant decreases in LKS and CLP/CMP populations (Figures 17a-b). 
Specifically, 0.117% and 0.508% of whole bone marrow cells are LKS and 
CLP/CMP populations, respectively, in Mdm2–/– p53515C/515C compared to 0.474% 
and 1.74%, respectively, in control Mdm2+/– p53515C/515C littermates at E18.5 
(Figures 17a-b).  
Postnatally, the differences were even more pronounced. Specifically, 
starting at P4, LKS (0.044% in Mdm2–/– p53515C/515C vs. 0.243% in control) and 
CLP/CMP (0.273% in Mdm2–/– p53515C/515C vs. 1.726% in control) populations were 
dramatically low in bone marrows of Mdm2–/– p53515C/515C mice (Figures 17a-b). At 
P6, LKS and CLP/CMP levels decreased further to <0.0103% and <0.075% of 
whole bone marrows, respectively, while control Mdm2+/– p53515C/515C consistently 
had significant higher levels (0.265% for LKS and 1.292% for  CLP/CMP  of  whole  
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Figure 16. Gating strategy to analyze LKS and CLP/CMP populations. (a) We 
first gated for normal Forward (size) and Side (granulation) scatter population. (b) 
Then dead cells are excluded using DAPI as positive marker for dead cells. (c) Live 
cells are next gated for Lineage-negative markers. (d) Finally the Lin–ckit+ Sca1+ 
population that represents HSC and Lin–ckit+Sca1–/low population that represents 
CLP/CMP are purified. Percentage of live cells is calculated. All data analyzed on 
FlowJo. 
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Figure 17. HSC and progenitors are not affected in fetal livers but ebb 
gradually after birth in vivo. (a) Percentage of LKS population of whole tissues 
from E14.5 fetal livers (FL), and E18.5, P4, P6, P8 and P10 bone marrows (BM). (b) 
Percentages of CLP/CMP population of whole tissues from same timepoints as in 
(a). Error bars represent standard error of the mean.  
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bone marrow) (Figures 17a-b).  These populations became almost extinct by P8 in  
Mdm2–/– p53515C/515C mice (Figures 17a-b). 
 
AnnexinV levels in LKS and CLMP population 
 Although we could not detect increased AnnexinV staining in whole bone 
marrows at P6 (Figure 13b), HSCs and progenitors could still be undergoing 
apoptosis. This is also suggested by the rapid ebbing of LKS and CLMP populations 
after birth. So, we analyzed apoptosis levels of LKS and CLP/CMP in E14.5 fetal 
livers and P6 bone marrows using AnnexinV staining. LKS and CLP/CMP 
populations from E14.5 fetal livers had less than 2% positive cells for AnnexinV in 
either genotype (Figures 18a-b). We also could not detect any increase of apoptotic 
activity in the LKS and CLMP cells of bone marrows that are still surviving at P6 in 
Mdm2–/– p53515C/515C pups (Figure 18a-b). Hence, like in the remaining 
hematopoietic compartment, apoptotic activity is not the major factor for depletion of 
HSCs and progenitors.  
 
Enriched HSC population is still defective in postnatal bone marrows. 
The LKS markers select for HSCs but not exclusively (Kiel, Yilmaz et al. 
2005). In order to further enrich for HSCs, we used two additional markers (CD48 
and CD150) previously identified by Morrison’s group to be highly enriched in HSCs 
in fetal livers and bone marrows (Kiel et al.; Blood paper). Specifically, 48% of LKS 
CD48– CD150+ cells, hereafter referred to as SLAM-LKS, are LT-HSCs. Hence, we 
included CD48 in our lineage depletion selection, and selected the ckit+ Sca1+ 
population for expression of CD150 (Figure 19).  
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Figure 18. Absence of apoptotic activity in LKS and CLP/CMP populations. 
Percentage of LKS (left) and CLP/CMP (right) populations that are AnnexinV 
positive in E14.5 fetal livers (a) and P6 bone marrows (b). Error bars represent 
standard error of the mean.  
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Figure 19. Strategy to gate for SLAM-LKS. Lineage and CD48 positive cells were 
gated out. Of the Lin– CD48– cells, we gated for c-kit and Sca1 double positive 
cells. Then Lin–CD48–Sca1+c-kit+ cells was gated for CD150 expression versus 
forward scatter (FSC-A). 
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Figure 20. SLAM-LKS population is the same in FL but significantly less in 
bone marrows. Percentage of SLAM-LKS populations from E14.5 fetal liver (a) and 
P6 bone marrow (b). Number of mice used in each experiment is indicated next to 
genotype. Error bars represent standard error of the mean.  
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In E14.5 fetal livers, there was no statistical difference between SLAM-LKS  
populations (p=0.69) (Figure 20a). 0.042% of Mdm2–/– p53515C/515C fetal liver cells 
were SLAM-LKS while 0.036% for Mdm2+/– p53515C/515C controls. As for P6 whole 
bone marrows, there was more than a 2 fold decrease in the SLAM-LKS population 
in Mdm2–/– p53515C/515C bone marrows as compared to control littermates (p=0.02) 
(Figure 20b). Specifically, 0.047% and 0.022% of Mdm2+/– p53515C/515C and Mdm2–/– 
p53515C/515C bone marrow cells, respectively, were  SLAM-LKS.  Accordingly, 
regardless of   mode of  assaying  or  enriching  for HSCs, this population was 
decreased in bone marrows of Mdm2–/– p53515C/515C pups but not in E14.5 fetal livers 
compared to control Mdm2+/– p53515C/515C littermates. 
 
Ex vivo hematopoietic activity 
Hematopoiesis ex vivo 
In order to evaluate the potential of HSCs and CLP/CMP ex vivo, we used 
M3434 methylcellulose cultures (STEMCELL Technologies), a common assay that 
measures differentiation capacity of hematopoietic stem cells and progenitors. 
Colonies are identified based on morphology. Specifically, we looked for burst-
forming unit erythroid (BFU-E) (Figure 21a), colony-forming unit granulocyte 
macrophage (CFU-GM) (Figure 21b) and colony-forming unit granulocyte erythroid 
monocyte and megakaryocyte (GEMM) (Figure 21c) colonies. We isolated whole 
tissues from yolk sac at E9.5, fetal livers at E14.5 and bone marrow at P2 and 
plated 20,000 cells in triplicate.  
Mdm2–/– p53515C/515C E9.5 yolk sacs (Figure 22a), E14.5 fetal livers (Figure 
22b) and P2 bone  marrows  (Figure 22c)  reflected  absence  of  any hematopoietic  
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Figure 21. Representative colonies for methocult. Showing GEMM/mixed colony 
(a) characterized by all cell lineages (granulocytic, erythroid and megakaryocytes) 
with a dense core; BFU-E (b) colonies characterized by grape-like structures; CFU-
GM (c) colony characterized by clear round cells which may also harbor a dense 
center but distinct from that of GEMM colony. Scale bar is 200 µm. 
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a.         b. 
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Figure 22. Methocult assays reflects absence of hematopoietic activity ex vivo 
of all tissues tested. Quantification of CFU-GM, BFU-E and GEMM colonies from 
methocult cultures of 20,000 Mdm2+/+ p53515C/515C, Mdm2+/– p53515C/515C and Mdm2–/– 
p53515C/515C yolk sac (YS) (a), whole fetal liver (WFL) cells (b) and whole bone 
marrow (WBM) (c) cells at E9.5, E14.5 and P2, respectively. Error bars represent 
standard error of the mean.  
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Figure 23. Less dense CFU-GM colony in Mdm2–/– p53515C/515C (a) compared to 
Mdm2+/– p53515C/515C (b). 
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activity ex vivo except for few CFU-GM colonies, while the same tissues from 
control Mdm2+/– p53515C/515C littermates grew in culture with no impediments 
(Firgures 22a-c.). Notably, the few CFU-GM colonies of Mdm2–/– p53515C/515C tissues 
that were visible were significantly smaller and uncondensed (Figure 23a) as 
compared to colonies from control genotypes (Figure 23b). In Mdm2+/– p53515C/515C 
cultures, CFU-GM colonies were the most predominant, followed by BFU-E and 
GEMM colonies for all tissues. Noteworthy, E14.5 fetal liver and P2 bone marrow of 
Mdm2+/+ p53515C/515C hematopoietic activity in methocult showed no significant 
differences for all lineages compared   to   Mdm2+/–  p53515C/515C (Figure 22b-c).  
Thus, the   methocult   ex vivo assays did not reproduce our in vivo results for fetal 
livers that showed normal LKS, LKS-SLAM and CLP/CMP populations. These 
differences suggested culture conditions were an impediment for growth in 
methocult. The major difference in culture versus in vivo is oxidative stress. 
 
Oxidative stress in hematopoietic tissues. 
Reactive oxygen species levels are elevated in Mdm2–/– p53515C/515C bone 
marrows 
As discussed in the introduction, ROS are major sensitizers of the 
hematopoietic system (Naka, Muraguchi et al. 2008). Whether ROS effects are 
mediated via the p53 pathway in the hematopoietic compartment is unknown. To 
examine ROS levels in fetal livers and postnatal bone marrows, we used 5-(and-6)-
carboxy-2',7'-dichlorofluorescein diacetate (DCFDA), a commonly used reagent to 
measure ROS levels in cells (Ito, Hirao et al. 2004; Liu, Cao et al. 2009). We chose 
E14.5 fetal liver and P6 bone marrow as representative embryonic and postnatal    
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Figure 24. Increased ROS levels in postnatal bone marrows of Mdm2–/– 
p53515C/515C mice. (a) ROS levels were measured in whole tissues (fetal livers (FL) 
and bone marrows (BM)) at E14.5 and P6 using DCFDA intensity as a readout. (b) 
Measurement of ROS levels with DCFDA in LKS populations of E14.5 fetal liver 
(FL) and P6 bone marrow (BM). Error bars represent standard error of the mean. 
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time points, respectively. ROS levels of whole fetal livers and LKS populations at 
E14.5 between Mdm2+/– p53515C/515C and Mdm2–/– p53515C/515C mice were not 
statistically different (Figures 24a-b).  
Postnatally, mice are exposed to atmospheric oxygen levels and hence we 
expected higher ROS levels in postnatal bone marrows as compared to E14.5 fetal 
livers. Indeed, Mdm2+/– p53515C/515C whole bone marrows and LKS populations had 
3.8 and 1.5 times more ROS, respectively, compared to the same populations in 
E14.5 fetal livers (Figure 24a-b). This indicates that ROS levels within the 
hematopoietic compartment is higher in bone marrows than fetal livers in normal 
Mdm2+/– p53515C/515C mice. Since all pups are littermates, we expected that ROS 
levels of Mdm2+/– p53515C/515C and Mdm2–/– p53515C/515C littermates to be the same at 
P6. To our  surprise,  Mdm2–/– p53515C/515C pups had 3.3  and 3 times higher  ROS  
levels in whole bone marrow and LKS populations, respectively, than Mdm2+/– 
p53515C/515C littermates at P6  (Figure 24a-b). These data showed that Mdm2–/– 
p53515C/515C bone marrows intrinsically generated more ROS in whole bone marrows 
and LKS populations.  
 
Activation of PIGs in postnatal bone marrows 
To address what instigated the higher rates of ROS and apoptosis in P6 
bone marrows of Mdm2–/– p53515C/515C mice compared to control littermates, we 
examined p53’s role in ROS. Interestingly, p53 can transactivate a set of ROS-
inducing genes dubbed p53-induced-genes (PIG) which lead to cell death detected 
by using a DNA binding dye (Polyak, Xia et al. 1997). Specifically, we examined 
mRNA levels of Pig1, Pig8 and Pig12 that are amongst the most highly induced p53 
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genes (Polyak, Xia et al. 1997). Pig1 is a member of galectin family that can 
stimulate superoxide production (Yamaoka, Kuwabara et al. 1995). Pig8 is also 
known as Ei24 and its expression is induced following etoposide treatment that is 
known to generate ROS (Lehar, Nacht et al. 1996). Pig12 also known as 
microsomal glutathione transferase homologue is involved in redox reactions (Lee 
and DeJong 1999).  
At P6, Pig1 and Pig8 levels were 2 (p=0.01) and 3 (p<0.0001) fold higher in 
Mdm2–/– p53515C/515C bone marrows as compared to control littermates (Figure 25a). 
Pig12 levels were the same at P6. Since Polyak et al. (1997) reported that p53 
activates Pig genes in a cascading manner, we examined expression of these 
genes in P10 whole bone marrows as well. Interestingly, Pig12 levels at P10 were 
2.8 fold higher (p=0.01) in moribund Mdm2–/– p53515C/515C mice as compared to 
control littermates (Figure 25b). Pig1 (p=0.49) and Pig8 (p=0.07) levels were not 
statistically different at P10 (Figure 25b). Hence, p53-dependent activation of PIG 
genes is contributing to elevated ROS levels in the hematopoietic compartment. 
 
Antioxidants treatment. 
NAC injections partially rescue HSC and CLP/CMP at P6  
N-acetyl Cysteine (NAC) is a commonly used anti-oxidant usually delivered 
in drinking water. Since Mdm2–/– p53515C/515C mice begin to lose their HSCs and 
progenitors a few days after birth, we injected pups at P3 and P5 with 1g NAC per 1 
kilogram body weight (equivalent to the dosage in drinking water for adult mice). 
Unfortunately, this technique was highly invasive and most of the pups from all 
genotypes injected died after the first injection.  
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Figure 25. Increase of PIGs in Mdm2–/– p53515C/515C compared to Mdm2+/– 
p53515C/515C mice. Measurement of transcript levels of Pig1, Pig8 and Pig12 from 
whole bone marrow (WBM) cells at P6 (a) and P10 (b) from Mdm2–/– p53515C/515C 
compared to Mdm2+/– p53515C/515C measured by Real Time RT-PCR and normalized 
to Gapdh levels. Error bars represent standard error of the mean. 
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Figure 26. Partial rescue of LKS and CLP/CMP populations upon treatment 
with antioxidant. (a) LKS populations of whole bone marrows at P6 for NAC 
treated and untreated mice. (B) CLP/CMP levels of whole bone marrows at P6 for 
NAC treated and untreated mice. Error bars represent standard error of the mean. 
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Figure 27. Rescue of bone marrow cellularity after NAC treatment. 
Representative H&E staining for P10 bone marrow of a Mdm2–/– p53515C/515C mouse 
treated with NAC (right) compared to untreated (left). Scale bar is 200µm. 
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Two Mdm2+/– p53515C/515C and two Mdm2–/– p53515C/515C pups survived and 
were sacrificed at P6 to look for changes in HSC and CLP/CMP populations. 
Interestingly, a modest but significant increase in both of these populations was 
prominent in Mdm2–/– p53515C/515C pups injected with NAC compared to untreated 
mice of same genotype (Figure 26a-b). Specifically, there was 4 fold (p=0.001) 
increase in LKS population of whole bone marrow (0.041% for treated compared to 
0.01% for untreated) and 7 fold (p=0.01) increase in CLP/CMP population of whole 
bone marrow (0.5 % for treated compared to 0.07% for untreated) (Figure 26a-b). 
The two Mdm2+/– p53515C/515C pups treated with NAC that survived had no significant 
differences in LKS and CLP/CMP populations compared to untreated genotype-
matched mice (Figure 26a-b). 
Notably, a third Mdm2–/– p53515C/515C mouse survived NAC injections at P3 
and P5 and received a third injection at P7 then sacrificed at P10 to look for 
changes in bone marrow cellularity. Interestingly, bone marrow cellularity was ~80% 
restored in the treated mouse compared to Mdm2–/– p53515C/515C untreated control 
(Figure 27).  
 
Rescue of ex vivo hematopoiesis at 3% oxygen 
These data suggest that ROS contributes to the hematopoietic defect in 
Mdm2–/– p53515C/515C mice. Our initial ex vivo assays were performed at 20% 
oxygen. We therefore examined hematopoiesis ex vivo at 3% oxygen levels. 
Specifically, 20,000 cells from E14.5 fetal livers and P2 bone marrows of the pups 
used in (Figures 22b-c) were plated in triplicate onto methycellulose and allowed to 
grow. Contrary to culturing in 20% oxygen, 3% oxygen levels allowed 
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hematopoiesis to proceed unimpeded and all Mdm2–/– p53515C/515C tissues formed 
CFU-GM, BFU-E and GEMM (Figure 28a-b). Hence, all Mdm2–/– p53515C/515C fetal 
livers and P2 bone marrows examined showed complete rescue of hematopoiesis 
in methylcellulose cultures at 3% oxygen. Notably, these colonies were large, 
condensed and indicative of normal progression of hematopoietic activity. These 
data indicate that oxidative stress was the major impediment for sustainable 
hematopoiesis in the absence of Mdm2 due to activation of p53R172P. 
 
NAC treatment in methocult does not rescue hematopoiesis 
 In order to address whether NAC can rescue ex vivo hematopoiesis, we 
added 1 mM NAC to E14.5 fetal liver methocult plates cultured at 20% oxygen 
every three days. Cells from the same fetal livers were cultured at 20% oxygen with 
or without NAC, and at 3% oxygen level in methocult. Supplementing NAC to 
methocult was not sufficient to rescue hematopoiesis and we saw no differences 
between plates with and without NAC of Mdm2–/– p53515C/515C fetal livers (Figures 
29a-b). Specifically, only few CFU-GM colonies grew out from Mdm2–/– p53515C/515C 
fetal livers after 10 days in culture. NAC did not affect cultures of Mdm2+/– 
p53515C/515C plates. On the other hand, 3% oxygen level, as already shown, was 
permissive  for  growth of Mdm2–/– p53515C/515C fetal livers ex vivo (Figure 29c). 
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Figure 28. Rescue of ex vivo hematopoiesis at 3% oxygen. 20,000 cells of 
Mdm2+/– p53515C/515C and Mdm2–/– p53515C/515C whole fetal livers (WFL) (a) and whole 
bone marrow (WBM) (b) cells were cultured at 3% oxygen and the number of CFU-
GM, BFU-E and GEMM colonies were quantified. Error bars represent standard 
error of the mean. 
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Figure 29. NAC treatment does not rescue ex vivo hematopoiesis. 20,000 
whole fetal liver cells were cultured from each mouse in triplicates at 20% oxygen 
without (a) and with (b) NAC, and at 3% oxygen (c). 
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Reestablishing hematopoiesis at 3% after 10 days of culturing at 20% oxygen 
 After 10 days of culturing Mdm2–/– p53515C/515C bone marrow cells at 20% 
oxygen and showing no growth, we transferred 2 plates to 3% oxygen incubators. 
Surprisingly, Mdm2–/– p53515C/515C cultures started growing again and within 10 days 
we had noticeable large colonies (Figure 30). As a control we kept Mdm2–/– 
p53515C/515C plates at 20% and even after 20 days of culture we could not detect any 
obvious increase in colony formation. Hence, although the cells at 20% oxygen did 
not grow, apparently they were in a dormant state until culture conditions allowed 
their growth.  
 
Analyzing p16 status and generating Mdm2–/– p53515C/515C p16–/– mice 
p16 is stable in Mdm2–/– p53515C/515C bone marrows  
p16 is a cyclin-dependent kinase inhibitor and can induce cell cycle arrest 
and its overexpression in HSCs inhibit their proliferation (Park, Qian et al. 2003; 
Akala, Park et al. 2008). p16 is also implicated in ROS regulatory pathways of 
HSCs. Specifically, loss of Atm confers severe hematopoietic stem cell defect 
characterized by elevated ROS levels (Ito, Hirao et al. 2004). ROS in this system 
activates p16 whose levels are dampened upon antioxidant treatment (Ito, Hirao et 
al. 2004). Moreover, restoring p16 expression in progenitors inhibits their expansion 
(Lewis, Chinswangwatanakul et al. 2001). Since ROS levels were elevated in 
Mdm2–/– p53515C/515C bone marrows, we examined p16 status using IHC. Although 
p16 mRNA levels were indistinguishable between Mdm2–/– p53515C/515C  and control 
littermates at  P6  (Figure 14b),  we  detected significantly elevated  p16 protein 
levels at P6, P8 and P10  in  Mdm2–/–  p53515C/515C  bone marrows  (Figure 31). Bone  
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Figure 30. Transfer of methocult to 3% oxygen restores hematopoiesis in P2 
WBM. 20,000 whole fetal liver cells were cultured from Mdm2–/– p53515C/515C P2 
whole bone marrow (WBM) and were incubated at 20% oxygen for 3 weeks (left). 
After 10 days at 20%, 2 plates from same mouse were transferred to 3% oxygen 
incubators and number of colonies was counted 10 days after (right). 
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Figure 31. p16 levels are higher in Mdm2–/– p53515C/515C bone marrows. a) 
Immunohistochemical staining of cytoplasmic p16 in P6, P8 and P10 bone marrows 
of Mdm2+/– p53515C/515C (left) and Mdm2–/– p53515C/515C (right) mice. Scale bar is 
50µm. 
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marrows of control Mdm2+/– p53515C/515C littermates had some positive cells for p16 
staining but much less than Mdm2–/– p53515C/515C mice (Figure 31). These data 
suggest that ROS in the hematopoietic compartment of Mdm2–/– p53515C/515C mice 
can induce p16 levels. 
 
p16 deletion rescues bone marrow cellularity and extends survival of Mdm2–/– 
p53515C/515C mice 
In order to address whether p16 deletion can restore hematopoiesis, we 
generated Mdm2+/– p53515C/515C p16–/– mice and crossed them to each other. 
Although, the size of these mice was smaller than normal and their pregnancy rate 
was low, they were still able to generate pups. Mdm2–/– p53515C/515C p16–/– mice still 
suffered from growth retardation. Three Mdm2–/– p53515C/515C p16–/– mice from two 
independent crosses were sacrificed at P10 (where bone marrow acellularity is 
most dramatic in Mdm2–/– p53515C/515C mice) and their bone marrows were stained 
with H&E for histological analysis. Interestingly, p16 deletion restores bone marrow 
cellularity by at least 70% (Figure 32). Also, Mdm2–/– p53515C/515C p16–/– mice lived 
significantly (p<0.0001) longer than Mdm2–/– p53515C/515C mice (Figure 33).  
 
Characterization of Mdm2–/– p53515C/515C p16–/– bone marrows 
P53R172P levels are elevated in Mdm2–/– p53515C/515C p16–/– bone marrows 
 In order to examine the mechanism behind rescue of bone marrow cellularity 
upon genetic deletion of p16, we first examined p53R172P levels in Mdm2–/– 
p53515C/515C p16–/– bone marrows by IHC at P10. p53R172P was still highly 
detectable  in  Mdm2–/–  p53515C/515C p16–/–  bone  marrows  indicating  that  p16  loss  
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Figure 32. p16 deletion partially restores cellularity of Mdm2–/– p53515C/515C 
bone marrow. H&E staining of P10 bone marrows from Mdm2–/– p53515C/515C (left) 
and Mdm2–/– p53515C/515C p16–/–  (right) mice. Scale bar is 200µm. 
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Figure 33. p16 deletion extends survival. Kaplan-Meier survival curve of Mdm2–/– 
p53515C/515C p16–/– mice (n=8) compared to Mdm2–/– p53515C/515C mice (n=26). 
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alleviates p53-independent pathways (Figure 34). We then examined the cell cycle 
status of Mdm2–/– p53515C/515C p16–/– bone marrows at P6. We expected that deletion 
of p16 should increase bone marrow cycling. Indeed, The fraction of cells in Mdm2–
/– p53515C/515C p16–/– bone marrows that were in S phase was two fold higher (12.9%) 
than bone marrows of Mdm2–/– p53515C/515C mice (6.5%) (Figure 35). This indicates 
that increased bone marrow cycling contributed to rescue of bone marrow 
cellularity. 
 
Mdm2–/– p53515C/515C p16–/– bone marrows have increased LKS and CLP/CMP 
populations compared to Mdm2–/– p53515C/515C bone marrows 
p16 deletion partially restored the bone marrow cellularity. Since LKS and 
CLP/CMP are responsible for replenishing the bone marrows, we asked whether 
p16 loss could contribute to rescuing these populations as well. To that end, we 
analyzed the LKS and CLP/CMP populations of Mdm2–/– p53515C/515C p16–/– mice 
compared to Mdm2–/– p53515C/515C bone marrows at P6. Indeed, there was a 
significant increase in both of these populations. Specifically, LKS populations 
increased by 4 fold (p=0.0002) to 0.041% in whole bone marrow upon deletion of 
p16 compared to 0.01% in Mdm2–/– p53515C/515C mice (Figure 36a). CLP/CMP levels 
increased 9 fold (p=0.0036) upon deletion of p16 and reached 0.68% of whole bone 
marrow (Figure 36b). Although LKS and progenitor levels did not return back to 
normal levels as in Mdm2+/– p53515C/515C mice, this increase was consistent and can 
explain the replenishment of bone marrow cellularity at P10. Mdm2+/– p53515C/515C 
p16–/– bone marrows had no significant changes in LKS or CLP/CMP populations 
compared to Mdm2+/– p53515C/515C bone marrows (Figure 36a-b).  
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Figure 34. p53R172P is high in Mdm2–/– p53515C/515C p16–/– bone marrows. 
p53R172P immunohistochemical analysis on P10 bone marrows (BM) of Mdm2–/– 
p53515C/515C (left) and Mdm2–/– p53515C/515C p16–/– (right) mice. Scale bar is 50µm. 
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Figure 35. Increase S phase in Mdm2–/– p53515C/515C p16–/– bone marrows. Cell 
cycle status of P6 whole bone marrow cells (WBM) of Mdm2–/– p53515C/515C with and 
without p16. Error bars represent standard error of the mean. 
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Figure 36. Partial rescue of LKS and CLP/CMP populations upon deletion of 
p16 from Mdm2–/– p53515C/515C mice. LKS (a) and CLP/CMP (b) populations of P6 
whole bone marrow of Mdm2–/– p53515C/515C  p16–/– mice compared to Mdm2–/– 
p53515C/515C mice. Error bars represent standard error of the mean. 
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c-kit analysis in Mdm2–/– p53515C/515C mice 
c-kit downregulation   
 c-kit, also known as CD117, is a tyrosine kinase receptor that is expressed 
on hematopoietic stem cells and progenitors (Okada, Nakauchi et al. 1991). Binding 
of Steel factor (Sl), c-kit’s ligand, activates a plethora of downstream targets that are 
involved in self-renewal, differentiation and expansion of hematopoietic stem cells 
and their progenitors (Kent, Copley et al. 2008). Mice mutant for c-kit or Sl have 
severe hematopoietic defects and die shortly after birth (McCulloch, Siminovitch et 
al. 1964; Trevisan, Yan et al. 1996). While loss of c-kit is detrimental, its 
overexpression is oncogenic (Masson and Ronnstrand 2009).  
 Using flow cytometric analysis, we noticed rapid depletion of c-kit positive 
population in postnatal bone marrows of Mdm2–/– p53515C/515C but not in their fetal 
livers (Figure 37). At E14.5, the fetal liver cells had no obvious defects in c-kit 
expression using flow cytometry. We next measured c-kit transcript levels in whole 
bone marrows using RT-PCR. c-kit levels were 5 fold (p=0.001) and 7 fold 
(p=0.0003) less in Mdm2–/– p53515C/515C mice compared to control Mdm2+/– 
p53515C/515C (Figures 38a-b).  
 
p53 does not bind c-kit promoter 
 Since c-kit loss of expression correlated with p53R172P expression, and 
since p53 can bind and inhibit transcription of some genes (Rother, Kirschner et al. 
2007), we investigated whether c-kit downregulation was p53-binding dependent 
using chromatin immunoprecipitation (ChIP). To that  end, we  used intestines  from  
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Figure 37. Ebbing of c-kit expression in postnatal bone marrows but not fetal 
livers of Mdm2–/– p53515C/515C mice. c-kit expression in Mdm2+/– p53515C/515C (left) 
and Mdm2–/– p53515C/515C (right) mice from fetal livers (FL) (upper two) and bone 
marrows (BM) (lower two). Pink gating designated the c-kit+ population after Lin– 
depletion. 
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Figure 38. c-kit mRNA levels are significantly lower at P6 and P10 in Mdm2–/– 
p53515C/515C bone marrows. c-kit mRNA expression measured with RT-PCR at P6 
(a) and P10 (b) of whole bone marrow (BM) cells from Mdm2+/– p53515C/515C and 
Mdm2–/– p53515C/515C mice. Error bars represent standard error of the mean. 
 
 
 
 
     88 
irradiated and non-irradiated wildtype mice, as the intestine is a highly responsive 
tissue for p53 activity. p53 binding on acetylcholine receptor (AchR) and Puma 
promoters were used for negative and positive controls, respectively. We screened 
the promoter region upstream of c-kit transcriptional start site with 7 different primer 
sets spaced by approximately 600 bases each and covering approximately 5000 
bases. Unfortunately, we could not detect any significant binding of p53 on the c-kit 
promoter (Figure 39).  
 
Characterizing the mesenchymal lineage 
Significant increase in Lin– Sca1+ c-kit–/low population 
 Multipotent mesenchymal strom cells (MSCs), also known as mesenchymal 
stem cells, constitute a rare population in the bone marrow that are responsible for 
forming the hematopoietic niche (Short, Brouard et al. 2001). Progeny of MSCs can 
form osteoblasts, chondrocytes or myoblasts which contribute to formation of 
muscle, fat, cartilage and bone (Dennis, Merriam et al. 1999; Pittenger, Mackay et 
al. 1999). The hematopoietic niche can dictate the capacity of HSCs to self-renew 
or differentiate (Walkley, Shea et al. 2007). Contrary to human MSCs, murine MSCs 
are ill-defined and hard to isolate due to dearth of information about their 
localization in the bone marrow and their very low numbers (Short, Brouard et al. 
2001).  
 Although Lin– Sca1+ c-kit–/low (hereafter referred to as MSC-like) population 
is a crude representative of MSCs, it can still delineate an understanding of the 
frequency of MSCs in Mdm2–/– p53515C/515C mice. We first noticed an obvious 
increase in  this population  when  gating for c-kit and  Sca1 after  lineage  depletion  
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Figure 39. Wildtype p53 does not bind the promoter region of c-kit. AchR and 
Puma are used as negative and positive control for p53 binding, respectively. 
Primers designed to amplify 7 regions of c-kit promoter designated as Reg1 to 
Reg9. IR (ionizing radiation) was used to induced p53 activity. Error bars represent 
standard error of the mean. 
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with  flow  cytometric  analysis  in   postnatal bone  marrows  but  not  fetal  livers  of 
Mdm2–/– p53515C/515C mice compared to control Mdm2+/– p53515C/515C littermates 
(Figure 37). E14.5 fetal livers of either genotype had approximately 0.11% of cells 
as MSC-like (Figure 40). At E18.5 bone marrows of Mdm2–/– p53515C/515C mice had 
almost two fold decrease (p=0.0088) in MSC-like cells. However, as early as P4, 
Mdm2–/– p53515C/515C bone marrows were three times more enriched for this 
population compared to control (Figure 40). This population then leveled off at P6 
with no significant differences between the two genotypes (p=0.37) (Figure 40). At 
P8 and P10, the MSC-like population differences started to become more 
pronounced in Mdm2–/– p53515C/515C mice as compared to control Mdm2+/– 
p53515C/515C mice (Figure 40).  
 
Increased osteoblastic and adipogenic activity of Mdm2–/– p53515C/515C mice in 
vitro 
 In order to evaluate the activity of MSC-like cells in vitro, we collected P6 
whole bone marrows of either genotype and plated them in low well densities using 
mesenchymal-specific media. Typically, cells are plated for a few days until 
fibroblastic-like colonies form. These colonies are then induced to differentiate to 
certain lineages depending on factors added to the media. Surprisingly, cultures of 
Mdm2–/– p53515C/515C bone marrows differentiated into osteoblastic lineage without 
any induction as seen by increased alkaline phosphatase staining (Figure 41).  
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Figure 40. Increase in MSC-like population in Mdm2–/– p53515C/515C bone 
marrows. Fetal livers (FL) and bone marrows (BM) were collected from designated 
time points and analyzed with flow cytometry for frequency of MSC-like population 
(Lin– Sca1+ ckit–). At  least three mice were used for each time point. Error bars 
represent standard error of the mean. 
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Figure 41. Increase osteoblastic differentiation of P6 bone marrows of Mdm2–
/– p53515C/515C mice in vitro. P6 whole bone marrows were allowed to grow for MSC 
colony formation. Mdm2–/– p53515C/515C (right) cells spontaneously differentiated into 
osteoblastic lineage as seen by red alkaline phosphatase activity while Mdm2+/– 
p53515C/515C (left) retained undifferentiated state. 
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Transplantation experiments 
P6 whole bone marrows of Mdm2–/– p53515C/515C rescue lethally irradiated mice 
The potential of HSCs to engraft into irradiated recipients and repopulate the 
blood is a readout for functionality of these cells (Ema and Nakauchi 2004). If 
donor-derived cells reconstituted all lineages in the recipient mice, HSCs are said to 
be functional in the new niche. The generation of two congenic C57/B6 strains 
distinguished by a leukocyte common antigen (CD45.1 vs CD45.2) allows us to 
distinguish between donor and recipient derived hematopoietic cells in 
transplantation experiments (Saga, Tung et al. 1986; Saga, Lee et al. 1990).  
In order to address whether the hematopoietic failure in Mdm2–/– p53515C/515C 
was due to intrinsic HSC failure, niche defects or both, we performed 
transplantation assays. Since our donor Mdm2–/– p53515C/515C and Mdm2+/– 
p53515C/515C mice were in a C57/B6 CD45.2+ background, we used 8-12 weeks old 
wildtype C57/B6 CD45.1 mice as recipients. We first retroorbitally transplanted 
0.5x106 whole bone marrow cells of wildtype CD45.2 mice into lethally irradiated 
CD45.1 as a positive control for transplantation experiments. 100% (5 out of 5) of 
transplanted mice survived several weeks post-transplantation (Figure 42). To 
ensure that the irradiation was effective, we irradiated two mice but did not 
transplant them with donor cells. These mice died within two weeks post-lethal 
irradiation. 
We then transplanted 0.5x106 whole bone marrow cells of P6 Mdm2+/– 
p53515C/515C pups to first validate that bone marrow cells at this time point can 
reconstitute hematopoiesis. 100% (5 out of 5) transplanted mice with Mdm2+/– 
p53515C/515C bone marrows survived until 4 weeks post-transplantation proving that 
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Mdm2+/– p53515C/515C HSC population is normal and can reconstitute hematopoiesis 
in irradiated recipients (Figure 42). On the other hand, 100% (5 out of 5) lethally  
irradiated  CD45.1  transplanted with 0.5x106  Mdm2–/–  p53515C/515C  whole bone 
marrow cells died within two weeks indicating that the HSC defect in Mdm2–/– 
p53515C/515C mice is intrinsic to HSCs and progenitors.  
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Figure 42: Kaplan-Meier survival curve of recipient CD45.1 mice after 
transplantation. 0.5x106 bone marrow cells of Mdm2+/– p53515C/515C and Mdm2–/– 
p53515C/515C were injected into lethaly irradiated CD45.1 recipients. n=number of 
mice injected per genotype 
 
 
 
 
 
     96 
DISCUSSION 
 
Circumventing Mdm2–/– lethality 
 Mdm2 is the major negative regulator of p53 and its loss is lethal at early 
stages of embryogenesis due to p53-dependent apoptosis (Jones, Roe et al. 1995; 
Montes de Oca Luna, Wagner et al. 1995). This phenotype impedes understanding 
the role of p53 regulation by Mdm2 in normal tissues and during homeostasis at 
later stages of development. With the availability of a p53515C hypomorphic allele, 
we were successful in generating Mdm2–/– p53515C/515C mice. Remarkably, Mdm2–/– 
p53515C/515C mice are indistinguishable from their control Mdm2+/– p53515C/515C 
littermates at birth despite the lack of Mdm2. Since p53R172P cannot transactivate 
apoptosis genes (Ludwig, Bates et al. 1996; Rowan, Ludwig et al. 1996), Mdm2–/– 
p53515C/515C mice bypass this early apoptotic barrier and are born at normal 
Mendelian ratios. Mdm2–/– p53515C/515C pups live up to two weeks after birth. 
However, they suffer from growth retardation during postnatal development due to 
lack of sufficient blood cells and adequate hematopoiesis to support growth. This 
provides us with a window of time to address several questions about the effect of 
Mdm2 loss and the stability of p53R172P in the hematopoietic compartment during 
embryogenesis and postnatally. We could not detect p53R172P stability until E18.5 
in bone marrows despite absence of Mdm2. One justification is the existence of 
other negative regulators such as Mdm4 or Cop1 that are controlling p53R172P 
levels in the absence of Mdm2 during embryogenesis.  
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p53 dependence 
The hematopoietic and postnatal growth retardation defects and survival are 
rescued upon deleting one p53 allele confirming that this is a p53-dependent 
phenotype. Mdm2+/– Mdm4+/– mice, carrying wildtype p53 alleles, suffer from similar 
hematopoietic defects to Mdm2–/– p53515C/515C mice (Terzian, Wang et al. 2007). 
Specifically, Mdm2+/– Mdm4+/– mice have growth retardation, acellular bone 
marrows, low cell counts in the blood and die shortly after birth (Terzian, Wang et al. 
2007). Additionally, Mdm2+/– or Mdmx+/– mice subject to sublethal irradiation die 
shortly after irradiation due to wildtype p53-dependent hematopoietic phenotype 
(Terzian, Wang et al. 2007). This demonstrates that the phenotypes in Mdm2–/– 
p53515C/515C are not due to the mutant p53 allele per se but due to p53 activity. This 
suggests that the bone marrow is a very sensitive tissue to elevated p53 levels. This 
could be due to the high turn-over rate in this tissue that requires adequate check-
points to avoid error propagation. Therefore, uninhibited p53 is deleterious for bone 
marrows and Mdm2 is indispensible for regulating p53 levels during homeostasis. 
 
p53R172P modes of action to abrogate hematopoiesis 
 The rapid depletion of bone marrow cellularity is achieved by the 
combinatorial effect of several p53 activities. First, the elevation of p21 and Ccng 
levels in postnatal bone marrows indicates activation of cell cycle arrest and is 
supported by significantly lower percentage of bone marrow cells in S phase of cell 
cycle in Mdm2–/– p53515C/515C bone marrows compared to control littermates. 
Senescence genes are also upregulated, further exacerbating the phenotype. This 
further supports the senescence activity of p53R172P as seen in a lymphoma 
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mouse model (Post, Quintas-Cardama et al. 2009). Although Puma and Noxa levels 
were significantly higher, a 2 fold increase in these apoptosis-inducing genes is 
unlikely to cause the dramatic loss of cellularity. Because of absence of apoptotic 
markers (cleaved caspase-3 and AnnexinV) in Mdm2–/– p53515C/515C bone marrows, 
other types of cell death may be occurring. This is evident from the high subG1 
peak in 3 out of 6 Mdm2–/– p53515C/515C mice and the rapid loss of cellularity of bone 
marrows within few days after birth. Unfortunately, the exact mode of cell death in 
bone marrow cells is still undetermined. Another mouse model that lacks the Mdm2-
p53 feedback loop has less Mdm2 expression and also reveals high sensitivity of 
bone marrows to wildtype p53 activity post irradiation (Pant, Lozano, unpublished 
data). Notably, like in our mouse model the major cause of cell death in these mice 
is not apoptosis (Pant, Lozano, unpublished data). Since p53R172P levels are low 
or undetectable in fetal livers, cells have a normal cell cycle pattern and are 
histologically normal. Hence, the hematopoietic phenotype is the result of p53-
dependent induction of cell cycle arrest, senescence and cell death, and the 
absence of apoptosis supports previous work (Ludwig, Bates et al. 1996; Rowan, 
Ludwig et al. 1996) showing no apoptotic activity of p53515C allele. 
  
Sensitivity of HSCs and progenitors to p53R172P 
HSCs, progenitors and hematopoiesis are normal in E14.5 fetal livers. One 
potent effect of p53R172P is the depletion of LKS population (which includes LT-
HSC and ST-HSC) and CLP/CMP populations postnatally. Remarkably, these 
cellular populations are unaffected up until E18.5 when hematopoiesis progresses 
in the bone marrows. Although bone marrows are supposed to be highly cycling at 
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postnatal time points and until three weeks after birth (Bowie, McKnight et al. 2006), 
in the absence of HSCs normal bone marrow cellularity cannot be attained. In other 
studies, an increase in p53 activity or levels due to Bmi1 or Cited2 nullizygosity 
depletes HSCs (Park, Qian et al. 2003; Akala, Park et al. 2008; Kranc, Schepers et 
al. 2009). In these studies, deletion of p53 partially or totally rescues HSCs in Bmi1 
or Cited2 null mice, respectively. Hence, the sensitivity of HSCs to elevated p53 
levels in these mouse models is consistent with our data.  
Upon further enriching for LT-HSCs with SLAM-LKS isolation, there are still 
significant differences between Mdm2–/– p53515C/515C and control Mdm2+/– 
p53515C/515C mice at P6. And consistent with histological analysis, the SLAM-LKS 
population is normal in the fetal liver. Tissue specific differences could contribute to 
these variations. For instance, there could be other negative regulators than Mdm2 
that are regulating p53 in fetal livers, such as Cop1 and Mdm4, but are not potent 
enough in postnatal bone marrows. Regardless of the method of enrichment of 
HSCs and progenitors, all essays confirm the sensitivity of these populations to 
elevated p53 levels.  
 
Elevated ROS levels in bone marrows compared to fetal livers: spatial 
versus temporal factors 
Since there were no detectable hematopoietic defects in fetal livers in Mdm2–
/– p53515C/515C embryos, we speculated that fetal livers could provide us with a 
hematopoietic resource for mechanistic and molecular studies ex vivo. 
Hematopoiesis of the fetal liver ex vivo is abrogated similarly to the in vivo postnatal 
bone marrows. Specifically, fetal liver hematopoietic cells of Mdm2–/– p53515C/515C 
     100 
embryos at E14.5 did not grow in methocult. This is indeed a surprising result and is 
contrary to our expectations. One major difference between in vivo (embryogenesis) 
and ex vivo (methocult) processes is higher oxidative stress in the latter. Culturing 
fetal livers at 20% oxygen levels induced higher oxicative stress while 3% oxygen 
levels consistently permit growth.  
In vivo, the elevated ROS levels in Mdm2+/– p53515C/515C bone marrows at P6 
compared to fetal livers at E14.5 of same genotype suggest that hematopoiesis in 
postnatal bone marrows proceeds under higher oxidative stress. These variations of 
ROS levels in vivo are due to several factors attributed to spatial or temporal 
variations.  The fetal liver could be a more potent hematopoietic niche in chelating 
and reducing ROS levels than the bone marrow. For instance, upregulating 
antioxidant genes could be one way of achieving this. The fetal liver could also be 
producing less free radicals compared to bone marrows due to less exposure to 
oxygen.  
As for temporal effects, metabolic activity produces ROS that eventually may 
accumulate (Eriksson 2007). By the time hematopoiesis is established in the bone 
marrow, enough ROS could have been built up. Noteworthy, embryos receive 
oxygen through exchange between maternal and fetal blood. Postnatally, neonates 
are exposed to direct atmospheric oxygen, which can be a stronger source for ROS 
generation. In either case, ROS can damage DNA and certainly induce p53 activity 
(Ko and Prives 1996). The one Mdm2 allele harbored in Mdm2+/– p53515C/515C mice 
is sufficient to dampen ROS-induced p53R172P levels. In the case of Mdm2–/– 
p53515C/515C mice, however, p53R172P goes uncontrolled in absence of Mdm2 and 
its levels surge wiping out the bone marrow compartment. A critical role for Mdm2 is 
to keep p53R172P in check in response to basal ROS levels during homeostasis.  
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p53: ROS-generator 
 Mdm2+/– p53515C/515C and Mdm2–/– p53515C/515C mice are housed in the same 
conditions. Yet, ROS levels in bone marrows of Mdm2–/– p53515C/515C pups are 
significantly higher than their control littermates. This suggests that Mdm2–/– 
p53515C/515C bone marrow cells are intrinsically generating more ROS. This is further 
validated by the significant upregulation of PIGs which are ROS-inducing genes and 
direct targets of p53 (Polyak, Xia et al. 1997). The surge of different PIGs at 
different time points (P6 versus P10) supports the temporal variation of their p53-
dependent upregulation as previously shown by Bert Vogelstein’s group (Polyak, 
Xia et al. 1997). ROS generation increases cell death and contributes to depletion 
of bone marrow cellularity. Maintaining elevated ROS could potentially create a 
positive feedback loop to keep p53R172P levels high and ultimately induce cell 
death. In the absence of Mdm2, this feedback loop cannot be broken. It would be 
interesting to address whether p53-induction of cell death in other tissues after 
stress, such as ionizing radiation, is also mediated through an increase in ROS 
production. This is a novel finding as it sheds light on an alternative mechanism of 
inducing cell death in the absence of p53’s normal apoptotic activity in the 
hematopoietic compartment. To our knowledge, this is the first observation of p53-
dependent production of ROS in an in vivo system in the hematopoietic 
compartment. 
  
ROS generation in hematopoietic compartment of other mouse models 
 Several studies correlated loss or gain-of-function of genes with elevated 
ROS in HSCs. For instance, Atm–/– mice accumulate ROS in their bone marrows 
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and HSCs in a mechanism that is still not clear (Ito, Hirao et al. 2004). On the other 
hand, mTOR overactivation due to targeted mutation of its negative regulator Tsc1 
stimulates mitochondrial ROS biogenesis (Chen, Liu et al. 2008; Chen, Liu et al. 
2009). This is concomitant with increased cycling of HSCs and ultimately loss of 
their “stemness”.  In another model, Bmi1 loss, a Polycomb repressor, impairs 
mitochondrial function and instigates higher ROS levels, thus damaging HSC 
activity (Liu, Cao et al. 2009). Genetic deletion of Chk2, a DNA damage response 
pathway and activator of p53, alleviates the Bmi1-dependent phenotype (Liu, Cao et 
al. 2009). Based on our model, we imagine that the Bmi1 effect is mediated through 
Chk2 activation of p53. This can be supported by the rescue of the effect of Bmi1 
loss on hematopoiesis by triple deletion of p53, p16 and p19 in a different study 
(Akala, Park et al. 2008). Hence, while one study correlated Bmi1 with ROS and 
Chk2, and another correlated Bmi1 with p53, our study links these studies by 
showing that regardless of the mode of activation of p53 (loss of Bmi1 or Mdm2, or 
activation of Chk2), p53 activates a set of ROS-inducing genes that lead to cell 
death and depletion of HSCs and their progenitors.   
 
Potential ROS effects on HSCs of Mdm2–/– p53515C/515C mice 
Collectively, the aforementioned studies provide enough evidence to support 
that high ROS levels can negatively influence HSC and progenitor activities. 
However, the exact mechanism remains an important question to explore. Elevated 
ROS levels in myeloid progenitors in Drosophila induces their differentiation via 
downregulation of Polycomb complexes and upregulation of JNK and FoXo 
signaling pathways (Owusu-Ansah and Banerjee 2009). Since p53 activates 
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differentiation pathways (discussed in introduction), this remains a plausible effect 
of p53R172P-dependent ROS production in Mdm2–/– p53515C/515C HSCs and 
progenitors. For instance, p53 can induce rapid differentiation of HSCs and 
progenitors into committed myeloid cells that are short-lived. Testing such a 
scenario would require lineage tracing of a SLAM-LKS sorted out population. The 
low abundance of this population in our mouse model remains an obstacle to 
address this question.  
Alternatively, as in the Atm–/– mouse model (Ito, Hirao et al. 2004), elevated 
ROS could have abrogated self-renewal capacity of HSCs in Mdm2–/– p53515C/515C 
mice. And since HSCs are typically highly cycling within the first three weeks after 
birth (Bowie, McKnight et al. 2006), ROS-dependent depletion of bone marrow 
cellularity could have “exhausted” the HSC pool and impaired their self-renewal 
capacity while trying to regenerate bone marrows. Additionally, localization of HSCs 
in the bone marrow is dictated by variations of oxidative stress intensities at 
different sites of the niche (Suda, Arai et al. 2005). It is possible that changes in 
ROS levels in HSCs of Mdm2–/– p53515C/515C mice altered their localization in the 
niche. Since HSCs acquire signals from the environment that dictate their potential 
to proliferate and differentiate, changes in their localization would hinder such 
signaling pathways. Hence, a p53-dependent increase of ROS levels in HSCs may 
obstruct their normal function, although exactly how this is achieved is still not clear. 
ROS activation of p16 has also been implicated in the hematopoietic 
compartment (Ito, Hirao et al. 2004). Treatment with antioxidants decreases p16 
levels and ameliorates hematopoietic activity (Ito, Hirao et al. 2004). However, a 
direct genetic proof is still lacking. p16 elevation in bone marrows of Mdm2–/– 
p53515C/515C mice further supports the ROS-mediated activation of p16. Here, we 
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provide the first genetic evidence that p16 deletion from HSCs predisposed to cell 
death due to Mdm2 deletion and p53 activation can mitigate cell death and partially 
expand this population, subsequently increasing bone marrow cellularity. Also, the 
same effect of p16 deletion is exerted on the CLP/CMP population. One explanation 
for this partial rescue is that p16 deletion increases the percent of cells in S phase, 
creating a reservoir of bone marrow cells. However, this is not sufficient to 
completely rescue the phenotype due to consistent elevation of p53R172P levels 
and persistence of other non-hematopoietic phenotypes. This indicates that p16 
deletion is affecting other pathways which are p53-independent. p16 loss increases 
the regenerative and self-renewal capacity of HSCs in transplantation studies 
(Janzen, Forkert et al. 2006). In a more recent work, Tariq Enver’s group clearly 
demonstrated that the deletion of both p16 and p19ARF can rescue Cited2–/– HSCs 
numbers and activity (Kranc, Schepers et al. 2009). This further supports our data 
that deletion of p16 can expand HSC and progenitor populations despite elevated 
p53R172P levels. 
 
 Antioxidants and rescue of hematopoiesis 
Pharamcological treatment of the antioxidant NAC rescues hematopoiesis in 
several mouse models with elevated ROS levels such as Bmi1–/– and Atm–/– (Ito, 
Hirao et al. 2004; Liu, Cao et al. 2009). However, in Mdm2–/– p53515C/515C mice NAC 
treatment produces only a partial rescue of progenitor and LKS populations. This 
could be attributed to several factors. For instance, the most common mode of 
administering NAC is generally in drinking water for adult mice. Since Mdm2–/– 
p53515C/515C mice are still lactating, we attempted to inject them with the drug 
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instead. However, most of the mice that were injected succumbed to toxic and 
invasive side effects regardless of their genotype. Also, we could not insure 100% 
delivery of the antioxidant in the two injections we administered.  Of the Mdm2–/– 
p53515C/515C mice surviving the treatment, LKS and CLP/CMP populations are 
significantly higher. Ideally, treated and untreated samples should have been 
analyzed at the same day. However, we could not get sufficient pups at P6 at the 
same time for this experiment. Since a significant increase in bone marrow 
cellularity occurred at P10 following NAC treatment, we conclude that NAC can 
partially rescue hematopoiesis. The rescue of hematopoietic activity ex vivo when 
hematopoietic tissues are cultured at 3% rather than 20% oxygen provides 
additional evidence that oxidative stress impedes hematopoietic activity.  
 
p53 and the supportive niche 
 HSCs integrate intrinsic and extrinsic signals in order to maintain 
hematopoiesis (Walkley, Shea et al. 2007). Extrinsic signals are provided by the 
cells of the hematopoietic such as osteoblasts and fat cells which are progeny of 
MSCs. Surprisingly, a distinct MSC-like population is predominant in Mdm2–/– 
p53515C/515C mice although this population is supposed to be low in bone marrows. 
Studies suggest that an increase in fat cell deposition can be a barrier for 
hematopoietic activity (Naveiras, Nardi et al. 2009). Specifically, irradiated human 
and murine bone marrows showed increased fat cell deposition which delayed 
homing of transplanted HSCs and regeneration of bone marrows (Naveiras, Nardi 
et al. 2009). In Mdm2–/– p53515C/515C bone marrows we clearly detect an increase of 
fat cell deposition using histological analysis at P10 when hematopoietic cells are 
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wiped out. Hence, the increase of adipocytes could be another factor for inhibiting 
hematopoiesis. The autonomous differentiation of P6 cultured bone marrows into 
osteoblastic lineages further support the evidence that while p53R172P is depleting 
hematopoietic activity, it also increases mesenchymal lineage activity. This goes 
against other studies showing that p53 inhibits osteoblastogenesis (Wang, Kua et 
al. 2006; Molchadsky, Shats et al. 2008). These studies use mouse embryonic 
fibroblasts to address the role of p53 in mesenchymal lineage differentiations. 
However, we use bone marrow cells which provide a more accurate representation 
of mesenchymal activity. One interesting hypothesis is that HSC marked by Lin– 
ckit+ Sca1+ could have lost or downregulated their expression for c-kit and switched 
to MSC-like population (Lin– ckit-/low Sca1+). The RNA levels of c-kit support a 
p53R172P dependent downregulation of c-kit. Although we couldn’t detect 
p53R172P binding to the promoter region of c-kit, p53R172P could be regulating c-
kit levels indirectly. Unfortunately, a c-kit transgenic mouse is not available to 
address whether c-kit overexpression can aid in rescuing hematopoiesis and 
restoring the LKS population. Hence, p53 exert various effects not only on the 
hematopoietic cells but also their environment. 
 Transplantation experiments remain the ultimate assay to address 
hematopoietic reconstitution activity. The failure of transplanted Mdm2–/– p53515C/515C 
bone marrow cells to rescue lethally irradiated wildtype mice confirms the intrinsic 
defects that Mdm2–/– p53515C/515C HSCs harbor. Mdm2–/– p53515C/515C hematopoietic 
cells could not respond to the normal signaling from the wildtype niche of the 
recipient mice. Alternatively, Mdm2–/– p53515C/515C hematopoietic cells could have 
failed to engraft and died while in circulation. On the other hand, Mdm2+/– 
p53515C/515C hematopoietic cells from same age are successful in engrafting and 
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reconstituting hematopoiesis of lethally irradiated mice. This result rules out the 
possibility that alterations in Mdm2–/– p53515C/515C niche, although still occurring, is 
triggering the defect in hematopoietic activity. 
  
Impact on Leukemia Stem Cells 
Until 1997, leukemia was perceived as a genetic or epigenetic disorder 
acquired by committed progenitors cells that allowed their unlimited proliferation and 
lack of differentiation (Passegue, Wagers et al. 2005). As discussed in the 
Introduction, p53 is a major regulator of both of these pathways. Using human acute 
myeloid leukemia (AML) cells John Dick was the first to show that the true cell of 
origin for leukemia could be a normal primitive cell (Bonnet and Dick 1997). More 
evidence for a normal HSC as origin of leukemia came from analyzing the AML1-
ETO, a hallmark of AML, status in patients in remission. Specifically, these patients 
had the AML1-ETO fusion in their normal HSCs (Miyamoto, Weissman et al. 2000). 
In addition to the fundamental characteristic of self-renewal, normal HSCs and 
LSCs share other features (Passegue, Jamieson et al. 2003; Passegue, Wagers et 
al. 2005). For instance, both cell types express CD34, lose expression of CD38, are 
dormant and give rise to progeny that are more differentiated (Passegue, Jamieson 
et al. 2003). Accordingly, it became apparent that pathways that sensitize normal 
HSCs could have similar effect on leukemia stem cells.  
We propose that p53 can be effective in inhibiting leukemiagenesis at various 
stages. Genetic aberrations or DNA damaging events in the HSC compartment can 
trigger p53 activity. Subsequently, p53 can halt cell cycle until damage is repaired or 
alternatively induce cell death. Our Mdm2–/– p53515C/515C mouse model clearly 
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demonstrated the sensitivity of HSCs and their progenitors to disruptions of Mdm2-
p53 levels. Given the similarities of HSCs and LSCs, it would be plausible that by 
exploiting the p53 pathway in leukemias, we can exert the same effect on LSCs and 
eradicate this population. The higher level of ROS by p53-dependent induction of 
PIGs in HSCs of Mdm2–/– p53515C/515C mice demonstrates a unique mode for 
induction of cell death in this population which can also be utilized in leukemia 
treatment.  
 
Suggested model 
 Increased ROS levels in bone marrows of Mdm2–/– p53515C/515C mice is a 
major finding of this study. In our model (Figure 43), we propose that hematopoiesis 
takes place under less oxidative stress while in the fetal liver compared to postnatal 
bone marrows. In a normal mouse, there would be sufficient Mdm2 to control p53 
levels. However, in the absence of Mdm2, p53 goes unchecked and triggers cell 
death, cell cycle arrest, ROS generation and senescence. Hence, although p53 is 
required to inhibit tumorigenesis and maintain genetic integrity, uncontrolled p53 
levels can be detrimental. The evolutionary existence of Mdm2 as a negative 
regulator of p53 provides protection against elevated p53 levels, although Mdm2 
can itself be oncogenic. Disrupting the balance between these proteins is indeed 
destructive to the organism. 
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Figure 43. Suggested model. Hematopoiesis progresses at low ROS levels during 
embryogenesis starting day 0. In bone marrows, ROS levels increase due to 
accumulation of metabolic products or direct exposure to oxygen after birth (green 
arrow time point). In a normal case, Mdm2 inhibits ROS activation of p53 and 
hematopoiesis proceeds normally in the fetal liver (FL) and bone marrows 
throughout adulthood. In absence of Mdm2, p53 goes uninhibited due to ROS 
dependent activation in the bone marrows. Subsequently, p53 induces more ROS 
and depletes hematopoiesis, hematopoietic stem cells (HSCs) and common 
lymphoid and myeloid progenitors (CLP/CMP).  
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Future directions and remaining questions 
This dissertation clearly demonstrates the deleterious effects of p53 on 
hematopoietic stem cells. It also briefly addresses the effects of p53 stability on the 
bone marrow niche. However, it would be interesting to decipher whether the 
Mdm2–/– p53515C/515C hematopoietic niche can support wildtype HSCs. Specifically, 
we propose to transplant GFP-tagged wildtype HSCs into Mdm2–/– p53515C/515C 
neonates of age P3 via the jugular vein and check for engraftment and 
reconstitution of hematopoietic activity. With GFP, we can trace cell fates and 
investigate whether HSCs would home to other hematopoietic organs such as 
spleen or liver if bone marrow niche were defective. Additionally, if wildtype HSCs 
completely reconstituted hematopoiesis, we ask whether a complete rescue of 
hematopoiesis is enough to significantly prolong the life of Mdm2–/– p53515C/515C mice 
to weaning age and beyond in the midst of other defects. 
p21 deletion prolonged survival of mice without rescue of hematopoiesis, 
while p16 rescued hematopoiesis. We propose to generate Mdm2–/– p53515C/515C 
p16–/– p21–/– mice and monitor hematopoiesis and survival. However, such a 
genetic cross is complicated and not necessarily achievable due to many allelic 
changes. If Mdm2–/– p53515C/515C p16–/– p21–/– mice survive, they can be monitored 
for tumor latency. Also, the reversible dormancy of Mdm2–/– p53515C/515C 
hematopoietic cells when cultured at 20% oxygen is a unique observation and 
requires further exploration. To that end, cells could be analyzed for senescence 
markers when cultured at 20% oxygen to confirm whether these cells are truly 
senescent and actually came out of senescence when cultured at lower oxygen 
levels. Investigating chromatin structure, senescent genes levels and b-
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galactosidase activity can aid in addressing this question. 
The Mdm2–/– p53515C/515C mouse model provides a genetic system to address 
the effect of p53 on other stem cells. Mdm2–/– p53515C/515C mice also suffer from 
cerebellar defects (Liu, Terzian et al. 2007). Since p53 induced such a dramatic 
defect on blood stem cells, is the same effect induced in neural stem cells? Are all 
normal stem cells susceptible to increased p53 activity in the absence of Mdm2 or is 
it just blood stem cells? Careful examination of other tissues in Mdm2–/– p53515C/515C 
mice would help resolve such questions. This is a pertinent discussion in the field as 
p53 is at the crossroads of aging, regenerative medicine, and cancer, all of which 
are correlated to stem cells. 
Finally, the obvious c-kit downregulation in the bone marrow is quite an 
intriguing observation and requires further research. We believe that some HSC 
population may still reside in the bone marrows of Mdm2–/– p53515C/515C mice. 
However, this population would lack c-kit expression and hence be incapable of 
undergoing hematopoietic activity. Loss of c-kit expression could be due to p53 
transactivation of genes that can inhibit c-kit transcription, leading to the latter’s 
downregulation. To address whether p53 is a major player in c-kit dowregulation, c-
kit+ cells from adult wildtype bone marrows can be sorted out. Subsequently, we 
can transfect p53 plasmid into these cells and monitor c-kit expression (RNA and 
protein) in these cells at various time points. c-kit is an oncogene in several 
hematological cancers and such a correlation with p53 can shed more light on the 
role of p53 in leukemia formation and treatment. 
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EXPERIMENTAL PROCEDURES 
 
Mice: We used previously described Mdm2+/– (Montes de Oca Luna, Wagner et al. 
1995) and p53515C/515C (Liu, Parant et al. 2004) mice  to make our Mdm2+/– 
p53515C/515C controls. These mice were bred to each other to generate Mdm2–/– 
p53515C/515C, Mdm2+/+ p53515C/515C and Mdm2+/– p53515C/515C littermates. Breeding 
cages were checked at least twice daily to monitor survival of pups. The day a plug 
was detected in females was designated as E0.5 and the day a litter was born was 
designated as P0.  All mice were at >90% C57BL/6 background as determined by 
marker analysis by Genetic Services at UT MD Anderson Cancer Center, Smithville. 
For genotyping, we extracted DNA from tail snips and PCR reaction was performed 
as previously described for p53515C (Liu, Parant et al. 2004), Mdm2 (Montes de Oca 
Luna, Wagner et al. 1995), p16 (Sharpless, Bardeesy et al. 2001) and p21 
(Brugarolas, Bronson et al. 1998). For antioxidant injections, NAC (A7250, Sigma-
Aldrich, MO, USA) was prepared in phosphate buffered saline and injected at P3 
and P5 at 1mg/g using a 28 gauge needle around the groin region. Pups were 
sacrificed at P6. All animal studies were approved by the Institutional Animal Care 
and Use Committee.  
Transplantation experiments: C57/B6 CD45.1+ mice were irradiated with a split 
dose of 5.5 Gy 4 hours apart. Two hours after the second irradiation, 0.5x106 cells 
whole bone marrow cells from P6 Mdm2–/– p53515C/515C and Mdm2+/– p53515C/515C 
mice were injected retroorbitally into isofluorane-sedated mice. Mice were 
monitored for survival on daily basis. For transplantation control, we used 0.5x106 
cells from adult C57/B6 CD45.2 widltype bone marrows as donors. For irradiation 
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control, two mice were irradiated without transplantation for each experiment.  
Histology and immunostaining of hematopoietic tissues: Pregnant females 
were sacrificed at designated time points. Neonates were decapitated. Tissues 
were either fixed in formalin for 48 hours then paraffin embedded for histological 
studies, or processed for RNA isolation and stem cell analysis as described below. 
For tissues, slides were sectioned at 6 µm and stained with Hematoxylin & Eosin for 
histology by the Department of Veterinary Medicine and Surgery Histology at UT 
MD Anderson Cancer Center, Houston. For immunohistochemistry, we used an 
antibody to p53 (#CM5, Vector Laboratories, CA, USA) at 1:500, p16 (#M-156, 
Santa Cruz Biotechnology, CA, USA) at 1:50 and cleaved caspase-3 (#9661, Cell 
Signaling, MA, USA) at 1:200 as previously described procedure (Post, Quintas-
Cardama et al. 2009). Hematoxylin (#H-3401, Vector Laboratories, Inc., CA, USA) 
was used as counterstain. 
RNA analysis: E14.5 fetal livers, and P6 and P10 bone marrows were 
homogenized and RNA was extracted using TRIzol (#155-96-026, Invitrogen, MD, 
USA) and treated with DNase (#04716728001, Roche, IN, USA) as previously 
described (Jackson and Pereira-Smith 2006).  First-strand DNA was generated by 
using First-strand cDNA synthesis kit from (#27-9261-01, GE Healthcare, NJ, USA). 
Bone marrows from two littermates of the same genotype were combined to provide 
an adequate amount of tissue to produce sufficient RNA for the experiment. Three 
combined pairs of littermates and one single mouse were used to generate an N of 
4 some experiments. Primer sequences are in Supplementary Table 2. All levels 
were normalized to Gapdh levels. 
Tissue homogenization and flow cytometry: After sacrificing the mice, tissues 
     114 
were washed with Hanks’ Balanced Salt Solution (HBSS) (#21-022-CV, Mediatech, 
Inc., VA, USA) supplemented with 2% Fetal Bovine Serum (#S11150, Atlanta 
Biologicals, GA, USA), 10mM Hepes Buffer (#25-060, Mediatech, Inc., VA, USA) 
and 1x Penicillin-streptomycin solution (#30-002, Mediatech, Inc., VA, USA), hence 
termed HBSS+. Then cells were kept in Dulbecco's Modified Eagle Medium 
(DMEM) (#10-107, Mediatech, Inc., VA, USA) with supplements as described for 
HBSS+. Fetal livers were homogenized with 181/2 G needle and passed through a 
40 µm filter (#342340, BD Falcon, NJ, USA). Bones from four limbs were gently 
isolated by removing any muscle or cartilage. Then, bone marrows were finely 
chopped, passed through 18G/12 needle and finally filtered through a 40µm filter. 
All cellular suspensions were kept on ice until further processing. For flow 
cytometry, murine HSC and MPP were identified using eBioscience (CA, USA) 
fluorochrome conjugated antibodies against ckit (PE_Cy7), Sca-1 (APC), and for 
lineage depletion we used CD4 (PE), CD8a (PE), B220 (PE), Ter119 (PE) and Gr-1 
(PE) in HBSS+. Mac-1 was not included in the lineage depletion cocktail as it is 
expressed in HSCs during late embryogenesis and early postnatal time points 
(Bowie, McKnight et al. 2006). For SLAM-LKS, we used CD48 (PE, eBioscience), 
CD150 (PE_Cy7, Biolegend) and c-kit (APC_H7, BDbioscience) in combination with 
Sca1 (APC, ebioscience) and Lin– markers. Cells were stained for 20 minutes in the 
dark on ice then washed with HBSS+ before analysis on BD LSRII System or BD 
FACSAria at UT MD Anderson Cancer Center Flow Cytometry Core Facility. Dead 
cells were excluded with 7AAD or DAPI staining (eBioscience, CA, USA). 
Cell cycle analysis: For cell cycle, tissues were fixed with 70% ethanol and kept at 
4 degrees until stained with propidium iodide (#P3566, Invitrogen, MD, USA). 
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Samples were analyzed on BD FACSCalibur System. Data were analyzed on 
FlowJo. 
AnnexinV staining: E14.5 fetal livers and P6 bone marrows were stained with 
FITC-conjugated Annexin V using ApoAlert Annexin V Apoptosis Kit (#630109, 
Clontech, CA, USA) according to manufacturer’s protocol. Briefly, cells were 
washed with the kit’s Staining Buffer for 2 minutes on ice, then incubated with 
Annexin V-FITC for 20 minutes on ice before running on BD LSRII System. For 
Annexin V staining on LKS, cells were stained for LKS markers first and then for 
Annexin V. Data were analyzed on FlowJo.  
ROS levels: For measurement of ROS levels, we used 2',7'-
dichlorodihydrofluorescein diacetate (2',7'-dichlorofluorescin diacetate; H2DCFDA) 
(#D-399, Invitrogen, MD, USA). 1 µM of DCFDA in DMSO was freshly prepared for 
each experiment. Then the stock was diluted in HBSS+ in 1:1000 factor for a final 
concentration of 1 nM DCFDA. After LKS staining, cells were stained with 1 nM 
DCFDA in HBSS+ at 37oC in the dark for 20 minutes. Cells were then washed and 
resuspended with HBSS+ at 37oC for recovery. Emission at 488nm wavelength was 
analyzed on BD FACSAria. Data were analyzed using FlowJo. 
Colony forming unit assay: After homogenizing tissues, live cells were counted 
with trypan blue. 20,000 cells were plated from each tissue, grown in 
methylcellulose media (#MethoCult M3434, STEMCELL Technologies, BC, 
Canada) and maintained in a mini-humidity chamber in 20% or 3% oxygen tissue 
culture incubators. Colonies were counted within two weeks after plating and 
identified based on morphology, specifically for CFU-GM, BFU-E and GEMM/Mixed 
colonies. In some experiments, NAC was added every three days at a final 
concentration of 1 mM. 
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Alkaline phosphatase staining: Whole bone marrow cells from P6 mice were 
plated on 6 well plates in αMEM media supplemented with 15% FBS. After 10 days, 
plates were washed and stained with Leukocyte Alkaline Phosphatase Kit (#86R, 
Sigma-Aldrich, MO, USA) as in manufacturer’s manual. Red dye deposition 
indicated alkaline phosphatase activity.  
ChIP assay: For ChIP, DNA was prepared as previously described (REFERNCE). 
Briefly, wildtype mice were irradiated at 6Gy then intestines were collected four 
hours later. CM5 antibody was used to pull-down p53-bound to DNA. Levels of DNA 
binding was measured using RT-PCR. Primer sequences are in Table 3.  
Statistics: Two-way t-test and Kaplan-Meier analyses were performed to assess 
statistical difference. A factor was considered statistically significant if it had a P-
value of <0.05.  
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Table 2. List of primers used for Real Time – PCR experiments. 
Gene Forward primer Reverse primer 
Ccng1 gcgaagcatcttgggtgtgt tcctttcctcttcagtcgcttt 
Dcr2 agctaacccagcccataatcgtc agttcccttctgacaggtactggc 
Dec1 ggagacctgtcagggatgga cccgcctggacttgtacact 
Gapdh tcaccaccatggagaaggc gctaagcagttggtggtgca 
Noxa tcgcaaaagagcaggatgag cactttgtctccaatcctccg 
p15 agatcccaacgccctgaac cccatcatcatgacctggatt 
p16 gccgcaccggaatcct tgcaccgtagttgagcagaaga 
p21 caggcaccatgtccaatcct gagacaacggcacactttgct 
Pig1 tggacacttccgaggttgtct cctcacggccccatttg 
Pig8 ggcatctgtaccatctcaaagct tcgacgctgttcctctctcttc 
Pig12 ggcttgggatccagagatgtc gtggcagagctgcagaaagaa 
Perp gctgcagccacgcttttc ggcgaagaacgagagaatgaa 
Pml gcacccgctgcaaagg tgagctgttcacactcgaaaca 
Puma gcggcggagacaagaaga agtcccatgaagagattgtacatgac 
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Table 3. List of primers used to span c-kit promoter. RE designates “Putative 
Response Element” region. 
Primer  Forward primer Reverse primer 
ckitRE
1 
CTCCAGGTGCGCTATGCA TGGGTGCTTTGCCTGTTTCT 
ckitRE
2 
TGTAGCGCCAGCACTTGTG AGCTGAGGATGGCTTTGAACTC 
ckitRE
3 
CCAACAGAGCAACACAAAGCA GAATAGGTTTCCCCCTCCATCT 
 
ckitRE
4 
GCGCAGCGTTCAACCTGTA CCTGAGACACCCACCTCACA 
 
ckitRE
5 
CAGGGCTCCCATCTCAGATC AGCGAGGCACTGTTAGTAGATGT
G 
ckitRE
8 
TGGAGAAACTGAGCATGAAAAA
TT 
GCACCCCTGACCTCAGTAAAAG 
 
ckitRE
9 
CCGGTGGTTGTCCTTTATTGTC 
 
GCCACGAGCGCATTAGGTA 
 
Puma GGACGGTCGCCTTGCA CACCTTAGTCCCAGTGATGAAA 
AchR FCCTCCCCCAACTCCACTTTT GGAGGTTGGAGGGAGAAGGA 
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APPENDIX 
 
Generation of Trim24 conditional knockout mouse 
Background and rational 
The levels of p53 in unstressed cells are consistently low and below a 
threshold that may induce apoptosis or cell cycle arrest (Jain and Barton 2009). The 
fine-tuning machinery responsible for controlling p53 levels is always expanding in 
the literature and includes but not limited to Mdm2 and Mdm4. In a screen for p53 
interacting proteins using mass spectroscopy, Alton et al. identified Trim24 as a 
novel negative regulator of p53 (Allton, Jain et al. 2009). Trim24 belongs to the 
tripartite-motif family of proteins characterized by an N-terminus containing a RING 
domain, Zinc finger binding B box domain and a coiled-coil domain (Meroni and 
Diez-Roux 2005). Trim24 acts an E3 ubiquitin ligase and targets p53 for 
proteosomal degradation in in vitro assays (Allton, Jain et al. 2009).  
Cop1 and Pirh2 are also negative regulators of p53 and target it for 
proteosomal degradation (Marine, Francoz et al. 2006). However, Cop1- and Pirh2-
null mice are not lethal (personal communication). This indicates that although 
certain proteins may play a role in regulating p53 levels in vitro, their biological 
significance remains controversial in mammalian systems. Trim24–/– mice have 
been recently generated and are tumor prone (Khetchoumian, Teletin et al. 2007). 
Specifically, Trim24 deletion impedes the withdrawal from cell cycle during 
neonatal-to-adult transition in liver cells and these mice develop metastatic 
hepatocellular carcinomas. These data do not support the oncogenic role of Trim24 
as a negative regulator of p53 as suggested by Alton et al.. On the contrary, they 
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show that Trim24 is a tumor suppressor. Noteworthy, the Trim24-null allele is 
generated by targeted deletion of its fourth exon. This leaves behind the first three 
exons which encode for RING domain. The E3 ubiquitin ligase activity of Trim24 is  
mediated via its  RING  domain 
a. 
 
 
 
b.  
 
 
c. 
 
 
 
 
Figure 44. Targeting strategy for Trim24. (a) Showing Trim24 wildtype locus 
spanning a 94.5 kb region. Targeting vector contains diphteria toxin and Neomycin 
(Neo) for negative positive selection, respectively. LoxP sites (triangles) inserted at 
each side of Exon 1. Neomycin cassette flanked by two Frt sites (tilted triangles). 
(b) Spe1 enzyme used to digest genomic DNA for southern blotting analysis with 5’ 
probe (5’) and 3’ probe (3’). Neo contains an Spe1 site which helps in detecting of 
right band size. Kpn1 and Sal1 sites denote the end of arms of homology. (c) 
Successful targeting of clone #F7 at 5’ end and 3’ end as shown by expected band 
size (12.6 and 9.5 kb). 
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(Allton, Jain et al. 2009). Hence, an incomplete deletion of its RING domain could 
have concealed the actual role of Trim24 to regulate p53. 
 
Summary of results 
To that end, we decided to generate a conditional knockout mouse of Trim24 
by genetic targeting of its first exon (Figure 44a). Using Southern Blotting, we were 
successful in identifying clone #F7 as correctly targeted for both 5’ and 3’ ends 
(Figure 44b-c). We then injected this clone into blastocysts of pseudopregnant 
females. Progeny with mixed coat color were bred to wildtype mice. The pups from 
this litter were analyzed for presence of Trim24Neo allele by PCR to determine if the 
allele was transmitted through germline (Figure 45).  
 
 
 
 
 
Figure 45. Representative PCR result to detect germline transmission. Lower 
band is wildtype while upper band represent Trim24Neo allele.  
 
We then generated Zp3-Cre Trim24Neo/+ mice by crossing Trim24Neo/+ mice to 
Zp3-Cre. Zp3-Cre Trim24Neo/+ females were mated to FLPeR  males. FLPeR male 
has the FLP recombinase ubiquitously expressed from ROSA26-locus (Farley, 
Soriano et al. 2000). FLP excised out the Frt sites and thus the Neo cassette. Also, 
Zp3 drives expression of Cre from the mouse zona pellucida 3 (Zp3) gene which is 
expressed in growing oocytes (Lewandoski, Wassarman et al. 1997). By Cre 
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recombinase activity, loxP sites are recombined and the first exon is excised 
leading to generation of a mouse with one of its Trim24 loci lacking Exon 1 hereafter 
designated as Trim24+/–. Trim24+/– mice were crossed to each other to generate 
Trim24–/– mice. Trim24–/– mice were born with no obvious defects.  
 
In order to investigate whether Trim24 is important for regulation of p53 post 
ionizing radiation (IR), we irradiated 8 weeks old Trim24–/– mice with 6Gy of IR. 
Mdm2+/– die within two to three weeks post sublethal irradiation (Terzian, Wang et 
al. 2007) and were used as positive control in this experiment. Mdm2+/– mice died 
as expected within 2-3 weeks post IR (Figure 46). However, all Trim24+/– and 
Trim24–/– mice survived 5 weeks post IR and had no obvious defects.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 46. Survival curve of mice post sublethal irradiation. Mice of indicated 
genotypes were irradiated with 6Gy and then monitored for survival. Number of 
mice used is indicated next to each genotype. Mdm2+/– mice died as expected. 
None of Trim24+/– orTrim24–/– mice died after 35 days. Mice were sacrificed then. 
wt= wildtype. 
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Discussion and future directions 
 The lack of lethal phenotype in Trim24–/– mice proves that the regulation of 
p53 by Trim24 is dispensable during embryogenesis. Since Trim24–/– mice do not 
die post sublethal irradiation, it is also not crucial for regulating p53 post radiation 
stress. These results indeed do not support the in vitro characterization of the role 
of Trim24 in regulation of p53. However, although Trim24 seems dispensable, it 
could be a minor player in the regulatory mechanisms of p53 in vivo. Its role in 
regulating p53 could be mediated through interactions with other proteins, such as 
Mdm2. To address this possibility, we will generate Trim24–/– Mdm2+/– mice and 
investigate whether the haplo-insufficiency of Mdm2 in the absence of Trim24 could 
exert any p53-dependent phenotypes. Additionally, we will monitor Trim24–/– mice 
for any tumor phenotypes that may arise. At the same time, we will perform whole 
mouse histological analysis on Trim24–/– mice and investigate whether there are 
any minor defects taking place. Trim24 regulation of p53 could be in certain cell 
types that their loss is not detrimental to the organism. Careful examination of all 
tissues should address this. Finally, we will examine p53 levels in Trim24–/– mice 
post irradiation. There could be a change in p53 levels compared to wildtype mice 
but not high enough to kill the mice. 
 
 Briefly, we were successful in generating Trim24–/– mice. These mice are 
viable and fertile. Trim24–/– mice are three months of age now and do not show any 
obvious defects. They are resistant to sublethal irradiation, unlike Mdm2+/– mice. 
Further investigation of the status of this allele is required to characterize these 
mice. It is still premature to conclude the significance of Trim24 regulation of p53 in 
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mammalian system in vivo. The survival of Trim24–/– mice suggests that Trim24-
regulation of p53 is not important during embryogenesis like Mdm2 and Mdmx. 
However, Trim24 can be important in certain tissues or after certain stresses 
postnatally which requires further investigation. 
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